COMPANY |
YEAR |
LOCATION |
BUSINESS MODEL |
MANAGEMENT |
FOCUS |
STAGE |
Abcys |
1999 |
IDF |
Design, Reagents |
Start-up | |
Cell |
Trade |
|
Paris |
Key words: Immunology, Cytokines, Cell culture, Stem cells, Production, Distribution, Third Parties, Gemstem |
Managing Dir.-CEO: Martin (Thierry) [born 1961] |
|
|
Mission: to design, manufacture and distribute biotechnology reagents, and to develop own research on Stem Cells |
Sc.Dir.-CSO: |
|
|
Clients: Research institutes, Hospitals, Universities, Pharmaceutical industry, Diagnostic industry |
Fin.Dir.-CFO: |
www.abcysonline.com |
|
Age: 21 year(s) |
BusDev: |
|
|
|
Financers (Hist.): undisclosed |
|
|
|
Communication : no website corporate information or press release since 2006 |
AB Science |
2001 |
IDF |
Discovery, Drugs |
Start-up | |
Cancers |
Clinical |
|
Paris |
Key words: Mastocytosis, Inhibitors, Tyrosine Kinase, Anticancer, Inflammation, Auto-immune diseases |
Managing Dir.-CEO: Moussy (Alain) [founder, born 1965, MBA Wharton, ENSTA, ex-Carrefour (Dir M&A)] |
|
|
Mission: to develop innovative tyrosine kinase inhibitors for auto-immune diseases in man and animals |
Sc.Dir.-CSO: |
|
|
Clients: Prescribers, Veterinarians |
Fin.Dir.-CFO: Guy (Laurent) |
www.ab-science.com |
|
Age: 19 year(s) |
BusDev: |
|
|
|
Financers (Hist.): privately owned (registered capital 2007 = 0.29 M€) |
|
|
|
note (September 2011) : sales are derived from masitinib in veterinary practice |
Adocia |
2005 |
Rhône-Alpes |
Discovery, Drugs |
Personal venture | |
Multiple |
Clinical |
|
Lyon |
Key words: Growth factors, Natural proteins, Regenerating organs, Osteoporosis, Diabetes, Aging population, BioChaperone |
Managing Dir.-CEO: Soula (Gérard) [born 1945, ex-Rhône Poulenc, Flamel Technologies (founder)] |
|
|
Mission: to develop innovative drugs for regenerating organs affected by diseases related to the aging of the population, such as osteoporosis and diabetes |
Sc.Dir.-CSO: Soula (Olivier) [born 1970, PhD polymer science, MBA-IAE (Lyon), ex-Flamel Technologies] |
|
|
Clients: Pharmaceutical industry |
Fin.Dir.-CFO: Danaguezian (Valérie) |
www.no-website.net |
|
Age: 15 year(s) |
BusDev: Soula (Rémi) |
|
|
|
Financers (Hist.): AGF P.E., Bioam Gestion, Société Générale A.M., Viveris Management, Business angels (Alain Tornier and Jean Deléage [died in 2011]), InnoBio, SHAM (Société Hospitalière d’Assurances Mutuelles) |
Advicenne Pharma |
2007 |
Méditerranée |
Discovery, Drugs |
Personal venture | |
CNS |
Preclin |
|
Castries |
Key words: CNS, Pediatry, Emergent diseases |
Managing Dir.-CEO: Granier (Luc-André) [founder, born 1954, Ph.D., M.D., ex-Forenap, Eli Lilly, Syntem] |
|
(near Nîmes) |
Mission: development and marketing of drugs for pediatric use mainly for the treatment of Central Nervous System Diseases (including autism, feeding behaviours dysfunctions and neurodegenerative disorders) |
Oper.Dir.-COO: Roussel-Maupetit (Caroline) [born 1969, Eng., ex-Syntem (co-founder), Protéine Performance] |
|
|
Clients: undisclosed |
Sc.Dir.-CSO: |
www.advicenne.com |
|
Age: 13 year(s) |
Fin.Dir.-CFO: |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): privately owned (registered capital 2007 = 0.13 M€), but CDC Entreprises with a board member |
|
|
|
Communication : website under development (March, September 2011, October 2012) |
Affichem |
2002 |
Midi-Pyrénées |
Design, Drugs |
Start-up | Managing Dir.-CEO: Silvente (Stéphane) [co-founder, born 1968, MBA, Ms. International Business, also chairman] |
Cancers |
Preclin |
|
Toulouse |
(also Design, Diagnostics) |
Sc.Dir.-CSO: Poirot (Marc) [co-founder, born 1960, also Inserm, Ph.D. chemical biology] |
|
|
Key words: Proteins, Dendrogenins, Cancer, Degenerative diseases |
Pharm.Dir.: Silvente-Poirot (Sandrine) [co-founder, also Inserm, Ph.D. molecular pharmacology] |
|
|
Mission: to develop drug candidates based on proprietary new family of compounds derived from sterols, Dendrogenines A and B, in cancer and neurodegenerative diseases |
Fin.Dir.-CFO: |
www.affichem.com |
|
Clients: Prescribers |
BusDev: |
|
|
Age: 18 year(s) |
Financers (Hist.): privately owned, undisclosed (opening of capital proposed to individuals in 2012, up to 8.6%) |
Agate Bioservices |
2005 |
Méditerranée |
Contract, Services |
Personal venture | |
Target |
Preclin |
|
Alès |
(also, Discovery, Targets) |
Managing Dir.-CEO: Chaabihi (Hassan) [founder, born 1962, Ph.D. molecular biology, ex-Protéines Performance, Quantum Biotechnologies] |
|
(near Nîmes) |
Key words: Gene expression, Protein production, Gene delivery, Insect cells expression, Baculovirus, BacTen |
Sc.Dir.-CSO: Chaabihi (Hassan) |
|
|
Mission: to provide third parties with services ranging from gene cloning to protein (or virus) production (resp. purification), acting as a vector developer, either for protein production or for gene transfer, as well as a manufacturing partner, to to develop new systems and technologies in the gene expression, gene transfer and delivery areas |
Fin.Dir.-CFO: |
www.agatebioservices.com |
|
Clients: Pharmaceutical industry, Biotech, Research labs |
BusDev: |
|
|
Age: 15 year(s) |
Financers (Hist.): privately owned (registered capital 2006 = 0.008 M€) |
|
|
|
Communication : no website news update since November 2006 |
Aisa Therapeutics |
2005 |
IDF |
Discovery, Drugs |
Personal venture | |
Inflammation |
Preclin |
|
Évry |
Key words: Vascular endothelium, Inflammation, Nanomolarity, Colitis, Cystic cancer, Nutraceuticals, Anti-stress |
Managing Dir.-CEO: d’Alessio (Patrizia) [founder, born 1952, M.D., Ph.D., ex-Inserm] |
|
(near Paris) |
Mission: to develop new anti-inflammatory molecules for rhumatoid arthritis, obesity, degenerative diseases, aging and metastatic spreading, based on the modulation-inhibition process in vascular permeability |
Sc.Dir.-CSO: |
|
|
Clients: pharmaceutical industry, veterinary industry |
Fin.Dir.-CFO: |
www.aisa-tx.com |
|
Age: 15 year(s) |
BusDev: Loumeau (Jean-François) [M.D., MBA] |
|
|
|
Financers (Hist.): Critt Chimie, Anvar |
Alfact Innovation |
2006 |
IDF |
Discovery, Drugs |
Personal venture | |
Cancers |
Preclin |
|
Paris |
Key words: Liver Failure, Liver Cancer |
Managing Dir.-CEO: Amouyal (Gilles) [born 1957, M.D., Ph.D.] |
|
|
Mission: to develop biopharmaceuticals for liver diseases |
Sc.Dir.-CSO: Bréchot (Christian) [M.D., Ph.D., V.P. Biomérieux, ex-Inserm] |
|
|
Clients: undisclosed |
Oper.Dir.-COO: Mariau (Jérémie) [M.Sc. human genetic, Eng. Supagro] |
alfactinnovation.com |
|
Age: 15 year(s) |
Fin.Dir.-CFO: |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): unknown (registered capital 2008 = 1.48 M€) |
Alizé Pharma |
2007 |
Rhône-Alpes |
Discovery, Drugs |
Start-up | |
Multiple |
Preclin |
|
Ecully |
Key words: Diabetes, Leukaemia, Recombinant L-asparaginase |
Managing Dir.-CEO: Abribat (Thierry) [co-founder, born 1964, Ph.D., Vet.D., ex-Sanofi-Recherche, Theratechnologies, OPi (CEO)] |
|
(near Lyon) |
Mission: to develop innovative therapeutics for the treatment of metabolic diseases and cancers (after early acquisition of products from Biotechs and in-house preliminary development) |
Sc.Dir.-CSO: |
|
|
Clients: Pharmaceutical industry |
Fin.Dir.-CFO: |
www.alz-pharma.com |
|
Age: 13 year(s) |
BusDev: Delale (Thomas) |
|
|
|
Financers (Hist.): Octalfa (Gilles Alberici, board member), CEMA (Canada, André de Villers, board member), SHAM (registered capital 2007 = 0.052 M€) |
Ambiotis |
2007 |
Midi-Pyrénées |
Contract, Services (also, Research, Drugs) |
Personal venture | |
Inflammation |
Subcontractor |
|
Toulouse |
Key words: Validation, Anti-inflammatory, Immunostimulatory, Biomarkers |
Managing Dir.-CEO: Dubourdeau (Marc) [founder, born 1973, M.D., Ph.D. immunology, Ms. Management (Toulouse)] |
|
|
Mission: to provide preclinical testing services (cellular and animal experiments) for anti-inflammatory and immunostimulatory assays of third parties, and to undertake own research specialized in the study of lipoxins, resolvins and protectins |
Sc.Dir.-CSO: Dubourdeau (Marc) |
|
|
Clients: Pharmaceutical industry, Cosmetics, Nutraceutics, Agro-food |
Fin.Dir.-CFO: |
www.ambiotis.com |
|
Age: 13 year(s) |
BusDev: |
|
|
|
Financers (Hist.): privately owned (registered capital 2007 = 0.04 M€) |
Anaconda Pharma |
2003 |
IDF |
Discovery, Drugs |
Spin-off | |
Cancers |
Preclin |
|
Paris |
Key words: Protein interactions, Condyloma, Anti-viral |
Managing Dir.-CEO: Blumenfeld (Marta) [born 1955, Ph.D. Biochemistry, ex-Genset] |
|
|
Mission: to develop a proprietary platform for the discovery of small molecules that disrupt protein:protein interactions, as a distinct unexploited class of pharmaceutical targets, due to the difficulty of recognizing drugable hot-spots on the surface of interacting proteins |
Sc.Dir.-CSO: |
|
|
Clients: Prescribers |
Med.Dir.: Compère (Delphine) [Ph.D. organic chemistry, ex-Pfizer, Cerep] |
www.anacondapharma.com |
|
Age: 17 year(s) |
Fin.Dir.-CFO: Bali (Ismahane) [Ms accounting, ex-Audit and Diagnostic] |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): privately owned (private investors) |
Aptys Pharmaceuticals |
2002 |
Centre |
Contract, Research |
Spin-off | |
Multiple |
Preclin |
|
Clermont-Ferrand |
(also, Delivery, Drugs) |
Managing Dir.-CEO: Boutignon (François) [co-founder, born 1960, Ph.D. protein biochemistry, ex-Europeptides] |
|
|
Key words: Formulation, Peptides, ADHAPT, Bi-Gel, Generic Plus, Insulin delivery |
Sc.Dir.-CSO: Boutignon (François) |
|
|
Mission: to develop formulation of new chemical entities and peptides/proteins, reformulation of registered molecules and novel drug delivery systems for third parties, to develop internal research programs for own technological portfolio, based on subcontractor cash flow |
Techn.Dir.-CTO: Barres (Thomas) [Ms.Sc., Pharm. D., ex-LPH Industries] |
www.aptys-pharmaceuticals.com |
|
Clients: Pharmaceutical industry, Biotechs |
Fin.Dir.-CFO: |
|
|
Age: 18 year(s) |
BusDev: |
|
|
|
Financers (Hist.): Sofimac Partners, Crédit Agricole Centre France, privately owned (registered capital 2007 = 0.10 M€) |
Ariana Pharmaceuticals |
2003 |
IDF |
Contract, Knowledge |
Spin-off | |
Data |
Subcontractor |
|
Paris |
Key words: Discovery acceleration, Virtual screening, Knowledge management, Decision support, KEM, eADMET, Bioassays |
Managing Dir.-CEO: Afshar (Mohammad) [co-founder, born 1966, Ph.D. biochemistry, ex-RiboTargets] |
|
|
Mission: to provide decision-support tools, in order to accelerate drug discovery of third parties |
Sc.Dir.-CSO: |
|
|
Clients: Pharmaceutical industry, Biotechs |
Tech.Dir.-CTO: Kuras (Mariana) [Ph.D. biophysics, ex-Biosystems, Pfizer] |
www.arianapharma.com |
|
Age: 17 year(s) |
Fin.Dir.-CFO: |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): privately owned, Institut Pasteur, Vizille Capital Innovation |
Aterovax |
2006 |
IDF |
Discovery, Development, Diagnostics and Immunology-vaccines |
Start-up | |
Cardiovasc |
1st product soon available |
|
Paris |
Key words: Tests, Atherosclerosis, sPLA2 Activity Test, Atherosclerosis Risk Assessment, Biomarker for Cardiovascular Risk Evaluation and Prevention, Secreted Phospholipase A2 Activity, In Vitro Diagnostic Assay, Immunotherapy |
Managing Dir.-CEO: Surun (Dominique) [M.D., MBA (CPA), ex-Meda Pharma, Janssen Cilag, 3M] |
|
|
Mission: to develop innovative solutions to predict, diagnose, prevent and treat cardiovascular diseases through a proprietary understanding of atherosclerosis |
Sc.Dir.-CSO: Valentin (Emmanuel) [Ph.D.] |
|
|
Clients: undisclosed |
Fin.Dir.-CFO: |
www.aterovax.com |
|
Age: 14 year(s) |
Regul.Dir.: Doceur (Paula) [Ph.D.] |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): SGAM (registered capital 2008 = 0.123 M€) |
|
|
|
Communication : website under re-construction (October 2012), legal undetailed changes at the end of 2011 – beginning 2012 (new chairman of the board, capital increase) |
Atlantic Bone Screen |
2005 |
Bretagne |
Contract, Services |
Personal venture | |
Inflammation |
Subcontractor |
|
Nantes |
Key words: Validation, In-vivo testing, Osteo-articular pathologies, LPRO |
Managing Dir.-CEO: Le Bot (Ronan) [co-founder, born 1977, Pharm.D.] |
|
|
Mission: to offer in vitro and in vivo (patented animal models) services dedicated to validation of proof of concept in osteoarticular pathologies, and (Atlanchim) to act as a subcontractor for the synthesis of new molecules |
Sc.Dir.-CSO: |
|
|
Clients: Pharmaceutical industry, Biotechs, Chemical industry, Food industry |
Fin.Dir.-CFO: |
www.atlantic-bone-screen.com |
|
Age: 15 year(s) |
BusDev: Porcher (Elisabeth) [MBA, ex-Eurocopter] |
|
|
|
Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€), internal growth (no outside investors searched) |
Aureus Sciences |
2000 |
IDF |
Contract, Knowledge |
Start-up | |
Data |
Subcontractor |
|
Paris |
Key words: Bioinformatics, Knowledge management, Molecular modeling, Data structuring, AurSCOPE, AurPROFILE |
Managing Dir.-CEO: Theodosiou (Jason) [born 1959, Ph.D. organic chemistry, MBA Sup de Co Paris, ex-MDL Information Systems, EMAX/SciQuest, LION Bioscience, Elsevier |
|
|
Mission: to provide knowledge management solutions to accelerate life science discovery for third parties |
Sc.Dir.-CSO: |
|
|
Clients: Pharmaceutical industry, Biotechs |
Dev.Dir.: Barberan (Olivier) [Ph.D.] |
www.aureus-sciences.com |
|
Age: 21 year(s) |
Fin.Dir.-CFO: |
|
|
|
MktgComm: |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): Bioam, AXA, FCJE (CDC), Matignon, OTC-AM |
|
|
|
Note : the news thread astutely mixes own events and general R&D major findings external to the company |
B Cell Design |
2008 |
Centre |
Discover, Drugs |
Personal venture | |
Cancers |
Proof-of-Concept |
|
Limoges |
Key words: Humanised antibodies |
Managing Dir.-CEO: Sainte-Laudy (Jean) [born 1946, Ph.D. immunology, ex-Pasteur Cerba] |
|
|
Mission: to develop, manufacture humanised IgA and IgG antibodies from genetically modified mice |
Sc.Dir.-CSO: Cuvillier (Armelle) [Ph.D. health biology] |
|
|
Clients: Clinical labs, Research labs, Medical imaging, Therapists |
Techn.Dir.-CTO: Champier (Gaël) [M.S. biotechnologies] |
www.b-cell-design.com |
|
Age: 13 year(s) |
Fin.Dir.-CFO: |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): Limousin Participation, Limousin Expansion, Limousin Business Angels |
BioAlliance Pharma |
1997 |
IDF |
Discovery, Drugs |
Start-up | |
Cancers |
Launch |
|
Paris |
(also Delivery, Drugs) |
Managing Dir.-CEO: Greciet (Judith) [Pharm.D., ex-Eisai, Wyeth, LFB, Zeneca, Pharmacia] |
|
|
Key words: Cancer, HIV, Opportunistic infections |
Oper.Dir.-COO: |
|
|
Mission: to discover, develop and market innovative treatments rapidly evolving therapeutic markets -cancer, serious viral diseases (such as HIV) and opportunistic infections- with NCE’s ans drug delivery improvements |
Med.Dir.-CMO: Attali (Pierre) [M.D., M.Sc., ex-Synthelabo, Sanofi, OSMO (co-founder), Molecular Engines Laboratories, Urogene] |
www.bioalliancepharma.com |
|
Clients: Prescribers |
Sc.Dir.-CSO: Kayitalire (Louis) [M.D., Institut Gustave Roussy, ex-Eli Lilly, B.M.S., Cephalon] |
|
|
Age: 23 year(s) |
Fin.Dir.-CFO: Fellman (Nicolas) [MBA, ex-Pfizer, Ernst & Young] |
|
|
|
SalesMktg: Dupré (Florence) |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): 3i, Auriga Partners, ING, Capricorn Venture, ABN-AMRO, SPEF Ventures, AGF P.E., Public |
|
|
|
Note : Financière de la Montagne (a company of family Besançon-Trébouta, previously holding Laboratoires Delagrange, part of Synthelabo, acquired by Sanofi) holds 10% of capital in December 2012 |
Biocortech |
2001 |
IDF |
Discovery, Drugs |
Spin-off | |
CNS |
Preclin |
|
Paris |
Key words: Neuro-psychiatric diseases, Biomarkers, Serotonin, Glutamate |
Managing Dir.-CEO: Weissmann-Pujol (Dinah) [co-founder, born 1951, Pharm.D., Ph.D. neurobiology, ex-Roussel Uclaf, CNRS] |
|
|
Mission: to develop novel biomarkers and treatments for psychiatric disorders, including depression, bipolar disorders, schizophrenia, and cognitive deficits |
Sc.Dir.-CSO: Pujol (Jean-François) [co-founder, M.D., Ph.D., Hospital Professor, ex-Roussel Uclaf, INSERM and CNRS] |
|
|
Clients: Pharmaceutical industry (own development, up to clinical trials) |
Fin.Dir.-CFO: |
www.biocortech.com |
|
Age: 19 year(s) |
BusDev: Allemand (Frédéric) [M.D. cardiology, ex-Hybrigenics, Bayer, Syngenta, Biovector Therapeutics, Hybrigenics, Genopole Entreprises, Medincell, Surfactis, Phenopro] |
|
|
|
Financers (Hist.): Institut Pasteur, business angels |
BioCydex |
2002 |
Aquitaine |
Delivery, Drugs |
Personal venture | |
Ophthamo |
Preclin |
|
Poitiers |
(also, Contract, Services) |
Managing Dir.-CEO: Belgsir (El Mustapha) [co-founder, born 1958, Ph.D., ex-CNRS] |
|
|
Key words: Ophthalmology, Cyclodextrins |
Sc.Dir.-CSO: Cenatiempo (Yves) [co-founder, also board chairman till 2008, born 1950, Prof. biochemistry (Poitiers)] |
|
|
Mission: to develop new compound formulations in ophthalmology, cancerology, and organ preservation during transplantation |
Fin.Dir.-CFO: Marembaud (Olivier) [born 1952, Engineer, ex-Frantour, Kelois, SNCF] |
www.biocydex.com |
|
Clients: Pharmaceutical industry (up to clinical stage) |
BusDev: |
|
|
Age: 18 year(s) |
Financers (Hist.): Oseo |
Biométhodes |
1997 |
IDF |
Contract, Manufacturing |
Personal venture | |
Haemophilia |
Trade |
|
Évry |
(also Design, Drugs) |
Managing Dir.-CEO: Amsallem (Gilles) [born 1954, ex-Mixis Genetics, Avesthagen (India), Dupont, Sorin Biomedica, Eurobio] |
|
(near Paris) |
Key words: Protein engineering, Mutagenesis, Enzymes, Service Contracts, Haemophilia, High throughput screening, Manufacturing processes, THR selection scheme |
Sc.Dir.-CSO: Winter (Bruno) [Ph.D., ex-AB Enzymes] |
|
|
Mission: to provide third parties with industrial processes based on proprietary know-how on improved enzymes, and to develop a next generation biologicals, with an initial focus on haemophilia, from sister company platform, Biométhodes Therapeutics |
Techn.Dir.-CTO: Langvad (Niels) [ex-Biodiesel (co-founder)] |
www.biomethodes.com |
|
Clients: Pharmaceutical Industry, Biotechs, Chemical industry, Animal food |
Fin.Dir.-CFO: Kazandjian (Raffy) [ex-CDC-Innovation Partners] |
|
|
Age: 23 year(s) |
BusDev: |
|
|
|
Financers (Hist.): CDC Innovation, CIC Capital, FCJE (CDC) |
Biom’up |
2005 |
Rhône-Alpes |
Development, Biomaterials & Medical devices |
Spin-off | |
Collagen |
Trade |
|
Saint-Priest |
(also, Contract, Manufacturing) |
Managing Dir.-CEO: Picot (Sylvain) [co-founder, born 1978, Ph.D., Insa], |
|
(near Lyon) |
Key words: Devices, Collagen, Glycosaminoglycans, Biopolymers, Grafting, Human reconstruction |
Sc.Dir.-CSO: Forest (Patricia) [co-founder, born 1978, Ph.D., Insa], also COO] |
|
|
Mission: to develop and manufacture innovative biopolymers, such as collagens, for implantable Medical Devices, with a special focus on long term applications, and to design customized Purification Tools, particularly in affinity chromatography |
Fin.Dir.-CFO: |
www.biomup.com |
|
Clients: Pharmaceutical industry, Cosmetic industry, Biotechs |
SalesDir.: Francy (Philippe) [Sup de Co] |
|
|
Age: 15 year(s) |
Financers (Hist.): privately owned, Créalys, SHAM, Sofimac Partners, Ameliane, Aquasourça, InnoBio, Viveris Management, OTC Asset Management |
BioProtein Technologies |
1998 |
IDF |
Contract, Manufacturing |
Personal venture | |
Multiple |
Preclin |
|
Jouy-en-Josas |
Key words: Therapeutic proteins, Gene expression, Transgenic rabbits |
Managing Dir.-CEO: Lignel (Jean) |
|
(near Paris) |
Mission: to provide third parties with production of recombinant therapeutic proteins and vaccines in the milk of transgenic rabbits, as a fully integrated service from gene expression to industrial production of purified proteins and vaccines |
Sc.Dir.-CSO: Ripoll (Pierre-Jean) [Ph.D., ex-Aventis, Biogemma] |
|
|
Clients: Pharma industry, Research labs, Biotechs |
Fin.Dir.-CFO: |
www.bioprotein.com |
|
Age: 22 year(s) |
BusDev: Fouassier (Alexandre) [Eng. INRA, M.Sc. biochemistry, also COO] |
|
|
|
Financers (Hist.): Société Générale A.M., Gilde, Creagro, Iwic, Anvar |
BioQuanta |
2003 |
IDF |
Contract, Research |
Personal venture | |
Cancers |
Patents |
|
Paris |
(also, Discovery, Drugs) |
Managing Dir.-CEO: Rabeuf (Rémi) [M.Sc. biology, MBA, ex-Roche (20 years)] |
|
|
Key words: Clinical biology, Biochemistry, Molecular modeling, In-silico Toxicity Prediction, In-vitro metabolic Exploration, Diagnostic kit and drug development |
Sc.Dir.-CSO: |
|
|
Mission: to promote predictive and personalized medicine |
Oper.Dir.-COO: |
www.bioquanta.com |
|
Clients: Biotech companies, Pharmaceutical, Food and Cosmetics industries |
Fin.Dir.-CFO: |
|
|
Age: 17 year(s) |
BusDev: Guidon (Romain) [MBA] |
|
|
|
Financers (Hist.): privately-owned (undisclosed private investors) |
BioSystems International |
2004 |
IDF |
Design, Diagnostics |
Spin-off | |
Multiple |
Trade |
|
Évry |
Key words: Biomarkers, Drug discovery improvement, Development productivity, Serum proteins |
Managing Dir.-CEO: Tirouflet (Jean-Pierre) [born 1950, ENA, ex-Rhodia (President), MEDEF, Rhône-Poulenc, Finance Ministry, Crédit National Bank |
|
(near Paris) |
Mission: to discover and validate biomarkers through partnerships with pharmaceutical, biotechnology and diagnostics companies and in-house research programs or academic collaborations |
Sc.Dir.-CSO: Takacs (Laszlo) [co-founder, born 1955, M.D., Ph.D., ex-Pfizer, Parke Davis, Amgen, NIH] |
|
|
Clients: Pharmaceutical industry (AstraZeneca), Biotechs |
Tech.Dir.-CTO: Guttman (András) [co-founder, Ph.D. Chemistry, ex-Beckman Coulter] |
www.biosys-intl.com |
|
Age: 16 year(s) |
Fin.Dir.-CFO: Hollai (Andrea) [MBA, ex-Hungarian Journalist’s Federation] |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): Société Générale |
|
|
|
Note : a susidiary (research) in Hungary |
BMSystems (Bio-Modeling) |
2004 |
IDF |
Discovery, Hub |
Start-up | |
Multiple |
Proof-of-Concept |
|
Paris |
Key words: Models, Proof of concept, Predictive efficacy, Validation, Spin-off |
Managing Dir.-CEO: Géa (Manuel) [co-founder, born 1960, Eng. Centrale, ex-Hemispherx (CEO), Boehringer-Ingelheim, Colgate-Palmolive, McKinsey] |
|
|
Mission: to help clients run their life sciences R&D programs better, faster, cheaper and safer by applying CADI methodologies and tools, an operational systems biology approach (mainly in the fields of infectious diseases, neurology, psychiatry, oncology, dermatology and innovative bioprocesses) |
Sc.Dir.-CSO: Iris (François) [also board chairman, born 1950, Ph.D., ex-Valigen (co-founder), Millenium] |
|
|
Clients: R&D departments (on a partnering basis), Financers (in case of spin-off) |
Med.Dir.-CMO: Dine (Gérard) [M.D., Ph.D.] |
www.bmsystems.net |
|
Age: 16 year(s) |
I.T.Dir.-CIO: Santamaria (Pablo) [Eng. Centrale, ex-Formitel, Glaxo] |
|
|
|
Fin.Dir.-CFO: |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): privately-owned (no search for external investors) |
Carmat |
2008 |
IDF |
Development, Device |
Spin-off | |
Cardiovasc |
Preclin |
|
Vélizy |
Key words: Artificial heart, Computer simulation, Electronic captors, Bioprothesis |
Managing Dir.-CEO: Conviti (Marcello) [born 1952, Ph.D., MBA, ex-Edwards Lifesciences, Sorin] |
|
(near Paris) |
Mission: to clinically develop, then market a fully implantable artificial heart for patients suffering in the aftermath of a massive heart attack or with late-stage heart failure and for whom standard drug therapy, ventricular assistance and/or a heart transplant have failed or are not possible |
Sc.Dir.-CSO: Carpentier (Alain) [born 1933, co-founder, M.D. (surgery), Hospital Professor] |
|
|
Clients: Hospitals |
Fin.Dir.-CFO: |
www.carmatsas.com |
|
Age: 12 year(s) |
MktgComm: Leroy (Valérie) [Ms. Mktg (Paris), ex-Toshiba Systèmes, Medtronic, Edwards Lifesciences] |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): Truffle Capital, Oseo, EADS |
|
|
|
Note : company first sourced as a J.V. Carpentier-Matra, in 1993 (company name, Carmat = Carpentier + Matra) |
|
|
|
Note : Internet showroom, available since June 2009 |
Cellectis |
2000 |
IDF |
Discovery, Therapy |
Spin-off | |
Genome |
Preclin |
|
Romainville |
(also Research, Subcontractor) |
Managing Dir.-CEO: Choulika (André) [co-founder, born 1965, Ph.D. virology], also chairman |
|
(near Paris) |
Key words: Genomic engineering, Meganuclease Recombination Systems (MRS), Proteins, DNA-repair |
Oper.Dir.-COO: Simon (Mathieu) [M.D., ex-Wyeth, Pierre Fabre] |
|
|
Mission: to research in, develop and market rational genome engineering technologies with 3 focus, manufacturing of proteins for therapeutic purposes, improvement of seed characteristics and development of treatments against single-gene disorders (myopathies, sickle-cell anaemia, etc.) and against the infections by DNA viruses (herpes, viral hepatitis, HIV, etc.) |
Sc.Dir.-CSO: Duchateau (Philippe) [Ph.D. science] |
www.cellectis.com |
|
Clients: Pharmaceutical industry, Biotechs, Agro industry, Research labs |
Tech.Dir.-CTO: Epinat (Jean-Charles) [Ph.D. science, ex-Institut Pasteur] |
|
|
Competitors: Applied Biosystems, 454 Life Sciences, Celera |
Fin.Dir.-CFO: Schwich (Pierre) [École des Mines (Paris), ex-Corning, Danone, Hewlett-Packard, 3i, Siparex, Next Venture)] |
|
|
Age: 21 year(s) |
BusDev: Sourdive (David) [co-founder, Ph.D. virology, Polytechnique, ex-CEO] |
|
|
|
Lic.Dir.-CBO: Pollet (Dirk) [Ph.D. biochemistry (Antwerp), ex-Dircs Consultant, Galapagos, Glaxo Welcome, Innogenetics] |
|
|
|
Comm.Dir.: Delassus (Sylvie) [Polytechnique (1983), Ph.D., ex-Institut Pasteur, Aventis] |
|
|
|
Financers (Hist.): Kaminvest, BankInvest, AGF P.E., Odyssée, Edmond de Rothschild, FSI, Bastid, Public |
|
|
|
Note: website revamping, in September 2010 |
|
|
|
note : the company has created a plant division in 2011, as a major diversification |
Cellial Technologies |
2001 |
North-Picardie |
Contract, Research |
Personal venture | |
Multiple |
Subcontractor |
|
Lens |
Key words: CNS research optimization, In vitro cell culture, Blood-Brain Barrier |
Managing Dir.-CEO: Leman (Sandrine) [born 1971, Ph.D., Institut Pasteur] |
|
|
Mission: accelerate CNS profiling and identify qualified leads candidates and eliminates the botleneck of drug transport accross Blood-Brain Barrier from clients’ discovery process |
Sc.Dir.-CSO: Berezowski (Vincent) [Ph.D.] |
|
|
Clients: Pharmaceutical industry, Biotechs, Academic labs |
Fin.Dir.-CFO: |
www.cellial.com |
|
Age: 20 year(s) |
BusDev: |
|
|
|
Financers (Hist.): Finorpa, Nord Innovation, Innovam |
|
|
|
Note : 2 additional round-table financing in 2007 and 2008 of undisclosed amount |
CellProthera |
2008 |
Alsace |
Discovery, Devices |
Personal Venture | |
Cardiovasc |
Proof-of-Concept |
|
Mulhouse |
Key words: Cell Therapy, Regeneration, Myocardial tissue |
Managing Dir.-CEO: Lataste (Xavier) [born 1949, Ph.D. clinical neurochemistry, M.D., ex-Sandoz, Novartis] |
|
|
Mission: to develop innovative stem cell therapy for the regeneration of myocardial tissue, allowing prevention of chronic heart failure after myocardial infarction |
Sc.Dir.-CSO: Hénon (Philippe) [founder, born 1938, M.D. Hematology, IRHT (founder, 1987), University Prof., also Board Chairman] |
|
|
Clients: not disclosed |
Oper.Dir.-COO: Jelsch (Jean-Claude) [CNAM, MBA (CPA, Lyon), ex-Ecco, Adecco] |
www.cellprothera.com |
|
Age: 12 year(s) |
Med.Dir.-CMO : Lataste (Xavier) |
|
|
|
Fin.Dir.-CFO: |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): privately owned, Financière Bendelé, Alsace Business Angels (registered capital 2008 = 0.05 M€) |
CellVax |
2001 |
IDF |
Contract, Services |
Personal venture | |
Cancers |
Subcontractor |
|
Évry |
Key words: Preclinical validation studies, Cancer, Viral diseases, Nodule, Angiogenesis model |
Managing Dir.-CEO: Wei (Ming) [co-founder, born 1963, Ph.D. molecular biology] |
|
(near Paris) |
Mission: to provide third parties with complete preclinical innovating services allowing to accelerate the drug development process in oncology field |
Sc.Dir.-CSO: Wei (Ming) |
|
|
Clients: Pharmaceutical industry, Biotechs, Public-sector labs (up to phase II) |
Med.Dir-CMO: Schatz (Christian) [M.D., Pharm.D., ex-Transgène] |
www.cellvax-pharma.com |
|
Age: 19 year(s) |
Fin.Dir.-CFO: |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€) |
|
|
|
Notes : website again active in 2010 ; no press release (or news) since 2007 |
Cerenis Therapeutics |
2004 |
Midi-Pyrénées |
Discovery, Drugs |
Personal venture | |
Cardiovasc |
Clinical |
|
Labège |
Key words: HDL therapy, Cholesterol, Atherosclerosis, Cardiovasculars |
Managing Dir.-CEO: Dasseux (Jean-Louis) [co-founder, born 1958, Ph.D., MBA, ex-Esperion Therapeutics (Pfizer), Fournier] |
|
(near Toulouse) |
Mission: to discover, develop and market next generation HDL therapies |
Oper.Dir.-COO: Brinkerhoff (William) [co-founder, MBA, ex-Esperion Therapeutics (Pfizer), Sankyo] |
|
|
Clients: Prescribers |
Sc.Dir.-CSO: Lalwani (Narendra D.) [Ph.D., MBA, ex-Parke Davis, Esperion, Pfizer] |
www.cerenis.com |
|
Age: 16 year(s) |
Fin.Dir.-CFO: Tupin (Cyrille) [CPA, ex-Sygnatures, PricewaterhouseCoopers] |
|
|
|
Med.Dir.-CMO: Paolini (John F.) [M.D., Ph.D., ex-Merck US, Bayer] |
|
|
|
BusDev: Brya (Tom) [MBA (Northwestern), MST, CPA, ex-Pharmacia, Monsanto/Searle, Cardinal Health, KV Pharmaceutical] |
|
|
|
Financers (Hist.): Sofinnova, HealthCap, Alta Partners, EDF Ventures, NIF Ventures, Daiwa Corporate Investment, TVM Capital, OrdiMed, FSI, Irdi-IXO |
CliniGenetics |
2000 |
Méditerranée |
Discovery, Drugs |
Personal venture | |
Cardiovasc |
Preclin |
|
Nîmes |
Key words: Atherothrombosis, Atherix pig model, Alive bio-informatics |
Managing Dir.-CEO: Falco (Jean-Louis) [born 1949, also board chairman, DEA Mkg-Finance Dauphine, ex-Schneider, Aurex (own consulting company)] |
|
|
Mission: to discover new therapeutics for the treatment of cardiovascular, cerebrovascular and lower limb ischemic diseases with a specific emphasis on atherothrombosis |
Sc.Dir.-CSO: Marguerie de Rotrou (Gérard) [born 1940, Ph.D., ex-Inserm, CEA, University Professor in Functional Genomics] |
|
|
Clients: Prescribers |
Fin.Dir.-CFO: |
www.clinigenetics.com |
|
Age: 20 year(s) |
BusDev: |
|
|
|
Financers (Hist.): BankInvest |
|
|
|
|
|
|
|
Notes (February 2012) : the company website is unavailable and the URL does not exist any more since 2010, but a legal process with board meeting occurred in August 2010 (still the same, in September 2011) and a board meeting occured in December 2011 and an AGM in August 2012 |
Covalab |
1995 |
Rhône-Alpes |
Design, Drugs |
Personal venture | |
Multiple |
Trade |
|
Villeurbanne |
(also Design, Diagnostics) |
Managing Dir.-CEO: El Alaoui (Saïd) [born 1955] & Thomas (Vincent) [born 1957] |
|
(near Lyon) |
Key words: Immunochemistry, MABs, Polyclonal antibodies |
Sc.Dir.-CSO: |
|
|
Mission: to supply innovative and unique polyclonal and monoclonal antibodies to third parties, such as universities, research institutes and commercial organisations around the world |
Fin.Dir.-CFO: |
www.covalab.com |
|
Clients: Research labs |
BusDev: |
|
|
Age: 25 year(s) |
Financers (Hist.): privately owned (registered capital 2007 = 0.24 M€) |
|
|
|
Communication: no website corporate news since 2005 |
Cytheris |
1999 |
IDF |
Discovery, Immunology |
Personal venture | |
Cancers |
Clinical |
|
Issy-les-Moulineaux |
Key words: Immune modulation, Cancer, HIV, HCV, Recombinant interleukin |
Managing Dir.-CEO: Marron (Damian) [born 1962, Pharmacologist, ex-3M Pharma, Orphan Europe, Rhône Poulenc Rorer, Glaxo, Nicox, Trophos] |
|
(near Paris) |
Mission: to discover and develop new therapies for immune modulation, by reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV and HCV, or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT) |
Sc.Dir.-CSO: |
|
|
Clients: Prescribers |
Fin.Dir.-CFO: Vannier (Bertrand) |
www.cytheris.com |
|
Age: 22 year(s) |
BusDev: Keatinge (Richard W.) [ex-BioAlliance Pharma] |
|
|
|
Financers (Hist.): Bioam, GestionT2C2/Bio, CDP Capital Technology Ventures, AXA P.E., Crédit Agricole P.E., CDC Innovation, Forbion, Caisse de dépôt et placement du Québec (Canada) (registered capital 2006 = 52.5 M€) |
Cytoo |
2008 |
Rhône-Alpes |
Contract, Research |
Personal venture | |
Consumables |
Trade |
|
Grenoble |
Key words: Adhesive micropatterns, High Content Analysis, Cell based assays, Cell Screening |
Managing Dir.-CEO: Chatelain (François) [co-founder, born 1965, ex-CEA, Protogene, Life Technologies, Genset, DNAgency] |
|
|
Mission: to develop, manufacture, and distribute products that make cellular analysis robust and reliable by drastically decreasing cell variability |
Sc.Dir.-CSO: Bornens (Michel) [co-founder, board member, ex-Pasteur Institute, Curie Institute] |
|
|
Clients: Pharmaceutical industry |
Oper.Dir.-COO: Fuchs (Alexandra) [co-founder, born 1969, Ph.D. biochemistry, Eng. Centrale, ex-CEA] |
www.cytoo.com |
|
Age: 12 year(s) |
Fin.Dir.-CFO: Fayand (Laurence) [EM-Lyon (MBA), ex-Fideco, Hewlett-Packard, Alditech, Crocus Technology (co-founder), Beamind] |
|
|
|
BusDev: Sharp (William) [also President-CEO Cytoo Inc.] |
|
|
|
Financers (Hist.): privately owned (registered capital 2008 = 0.1 M€), Auriga Partners, CEA Valorisation, Rhône-Alpes-Création, Expansinvest, Jacques Lewinern, Sham and Entrepreneurs Fund |
DBV Technologies |
2002 |
IDF |
Discovery, Diagnostics, Immunotherapy |
Start-up (speciality pharma company) | |
Allergy |
Trade |
|
Boulogne Billancourt |
Key words: Allergies, Viaskin, Epicutaneous Immunotherapy, Diallertest |
Managing Dir.-CEO: Benhamou (Pierre-Henri) [born 1955, M.D. Paediatrics] |
|
(near Paris) |
Mission: to develop an innovative non invasive delivery technology, Viaskin, worldwide patented, suitable for severe allergic patients to food allergy both in diagnosis and specific epicutaneous immunotherapy (EPIT) |
Sc.Dir.-CSO: Benhamou (Pierre-Henri) (also, CEO) & Dupont (Bertrand) [Ensam] |
|
|
Clients: Pharmaceutical industry, Food industry, Cosmetics |
Pharm.Dir.: Martin (Laurent) [Pharm.D., MBA IAE Paris, ex-Orphan Europe, Galderma, Fournier, Guerbet] |
www.dbv-technologies.com |
|
Age: 18 year(s) |
Clin.Dir: Agbotounou (Wence) [Ph.D. pharmacology, MBA ESCP, ex-Quintiles, PRA International] |
|
|
|
Fin.Dir.-CFO: Schilansky (David) [Dauphine University, Imperial College London, ex-Ipsen, UBS Warburg, Thomson] |
|
|
|
Dvpt. Dir: Ruban (Charles) [ex-Stallergènes, Europgroup Centrale (Lyon), Ms.Sc, Biomedical Engineering (Harvard-M.I.T), MBA (INSEAD) |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): Cap Décisif, Créagro, Sofinnova Partners, Apax Partners, ALK-Abello (Pharma company), InnoBio, Lundbeckfond Ventures, Shire, Alto Invest, Fonds Stratégique d’Investissement (FSI), Public |
Diaxonhit |
1997 |
IDF |
Discovery, Diagnostics |
Personal venture | |
Genome |
Trade |
|
Paris |
(also, Discovery, Drugs) |
Managing Dir.-CEO: Maurel (Loïc) [M.D., ex-Debiovision, Novartis, Rhône Poulenc Rorer] |
|
|
Key words: RNA splicing, Gene profiling technology, Cancer, Alzheimer |
Sc.Dir.-CSO: Pando (Matthew) [Ph.D. molecular biology] |
|
|
Mission: to leverage on alternative RNA splicing, the process by which a single gene can lead to several proteins in the fields of drug discovery, diagnostics and biochips and to sell proprietary gene profiling technology named Datas in order to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease |
Fin.Dir.-CFO: Duchesne de Lamotte (Hervé) [MBA, Ms (MIT), ex-Stanford Research Institute, AT Kearney France, IDM, Cirrus Finance Management] |
www.diaxonhit.com |
|
Clients: Pharmaceutical industry (own development up to phase II) |
C.O.O.: (Diagnostics Division) Barber (Isabelle) [Ph.D. organic chemistry, ex-Isis Pharmaceuticals, Genset, Ortho Clinical Diagnostics (J&J)] |
|
|
Age: 23 year(s) |
C.O.O.: (Therapeutic Division) Pando (Matthew) [Ph.D. molecular biology] |
|
|
|
BusDev: |
|
|
|
Comm.Dir.: Hoff (Corinne) [ex-Nicox, Aventis, Novartis)] |
|
|
|
Financers (Hist.): CDC Innovation, Sofinnova, Oxford Bioscience Partners, AGF P.E., BNP P.E., Dresdner Kleinwort, Danske Bank, LCF Ed. de Rotschild, Sudinnova, Biomérieux (5.8%, end 2007), Public |
DNA Therapeutics |
2006 |
IDF |
Discovery, Drugs |
Personal venture | |
Cancers |
Preclin |
|
Évry |
Key words: Cancer, siDNA, DNA repair |
Managing Dir.-CEO: Sun (Jian Sheg) [born 1959, also board chairman, Ph.D.] |
|
(near Paris) |
Mission: to develop proprietary siDNA (signal interfering DNA) technology platform and molecules, interfering with DNA damage repair mechanisms, to fight treatment-resistant cancers |
Sc.Dir.-CSO: Sun (Jian Sheg) |
|
|
Clients: Prescribers |
Res.Dir.: Dutreix (Marie) [Ph.D, CNRS (Institut Curie)] |
www.dna-therapeutics.com |
|
Age: 14 year(s) |
Fin.Dir.-CFO: Cervera (Bruno) [also, Actinnov (CEO), ex-Neurotech] |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): Blue Medical Investment, Inserm Transfert |
Domain Therapeutics |
2001 |
Alsace |
Discovery, Drugs |
Personal venture | |
CNS |
Clinical |
|
Illkirch Graffenstaden |
Key words: Neurological disorders, Neurotransmitter modulation, GPCR, Neuroclide, Glutamate inhibitor, Utrophin inducer, Parkinson, Alzheimer, Schizophrenia, Diabetes |
Managing Dir.-CEO: Neuville (Pascal) [co-founder, born 1964, Ph.D. molecular biology, ex-Transgene, Assistant Professor] |
|
(near Strasbourg) |
Mission: to discover and develop new treatments notably (but not only) for neurological and metabolic disorders, with an exclusive focus on GPCR-mediated neurotransmitter modulation |
Sc.Dir.-CSO: Neuville (Pascal) & Bossi (Laura) [M.D. neurologist, ex-Sanofi, Synthélabo] |
|
|
Clients: Prescribers Pharmas and Biotechs (own development up to phase III Preclinical candidate) |
Fin.Dir.-CFO: |
www.domaintherapeutics.com |
|
Age: 19 year(s) |
BusDev: |
|
|
|
Financers (Hist.): Sofinnova Partners, Auriga Partners, La Compagnie Financière de Rothschild, Siparex, AGF P.E., FCJE, Airfi (Alsace Inter Regio Fonds d’Investissement) and Alsace Création, plus Sam Eletr and Bernard Gilly |
|
|
|
Communication: the company was named Faust Pharmaceuticals from inception till December 2008, with URL as www.faustpharma.com |
Dynabio |
1992 |
Méditerranée |
Design, Diagnostics |
Personal venture | |
Multiple |
Preclin |
|
Marseille |
Key words: Stress proteins, Pancreatitis-Associated Protein (PAP), PancrePAP kit |
Managing Dir.-CEO: Broto (Ruben) [born 1937] |
|
|
Mission: to develop new immunological tools to improve detection of Pancreatitis-Associated Protein (PAP), as a new class of stress proteins whose expression reflects with extreme sensitivity pathological alterations of several tissues in the gastrointestinal tract |
Sc.Dir.-CSO: |
|
|
Clients: Research labs |
Oper.Dir.: Slagel (Dean) [born 1970] |
www.dynabio.com |
|
Age: 28 year(s) |
Fin.Dir.-CFO: |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): privately owned |
|
|
|
Communication: no website news update since 2006, extremely limited media information since inception |
Edelris |
2005 |
Rhône-Alpes |
Contract, Research |
Spin-off | |
Multiple |
Subcontractor |
|
Lyon |
Key words: Screening, Medicinal chemistry, Small molecules, Mimetics, CombiChem |
Managing Dir.-CEO: Ortholand (Jean-Yves) [co-founder, born 1965, Ph.D., ex-Bayer, Rhône Poulenc Santé, Merck Santé] |
|
|
Mission: to design and produce innovative, therapeutically relevant, natural-mimetic screening compounds, in order to accelerate the hit-lead discovery process in pharmaceutical and biotech research organizations |
Sc.Dir.-CSO: Greiner (Alfred) [co-founder, Ph.D., ex-Rhône Poulenc] |
|
|
Clients: Pharmaceutical industry |
Fin.Dir.-CFO: |
www.edelris.com |
|
Age: 15 year(s) |
BusDev: |
|
|
|
Financers (Hist.): |
|
|
|
Note: no legal accounting report since 2005 |
Endotis Pharma |
2003 |
IDF |
Discovery, Drugs |
Start-up | |
Multiple |
Preclin |
|
Romainville |
Key words: Small-glyco drugs (SGD), Thrombosis, Cancer |
Managing Dir.-CEO: Woller (Charles) [born 1949, M.D., Ph.D. Clinical pharmacology, MBA, ex-Neuro3D (founder), Cadus, Roche France (Managing Director), Warner Lambert, Akzo] |
|
(near Paris) |
Mission: to discover and develop Small-glyco drugs (SGD) for application in thrombosis and oncology |
Sc.Dir.-CSO: Petitou (Maurice) [Ph.D., ex-Sanofi, Lauréat Prix Charles Mentzer 2009] |
|
|
Clients: Prescribers |
Fin.Dir.-CFO: Degove (Stéphane) [Sup de Co (Paris), ex-Sanofi, Orica, OC&C] |
www.endotis.com |
|
Age: 17 year(s) |
BusDev: Henrard (Denis) [Ph.D. biochemistry , also DHC, ex-BD Medical, Elixir Pharmaceuticals, Johnson & Johnson, Abbott] |
|
|
|
Financers (Hist.): Endeavour Vision, NIF SMBC Ventures, Sofinnova Partners |
Epixis |
2003 |
IDF |
Discovery, Immunology |
Personal venture | |
Virus |
Preclin |
|
Paris |
Key words: Flu, C-Hepatitis, Mimetic particles, Virus-like particle vaccines |
Managing Dir.-CEO: Dalba (Maria) [born 1967, M.D., Ph.D.] |
|
|
Mission: to develop a platform technology for a new generation of Virus-Like Particle vaccines (eVLP) that may allow to quickly manufacture seasonal or pandemic flu vaccines, to treat Hepatitis C, and to be applied to other infectious diseases, such as HPV or HIV |
Sc.Dir.-CSO: |
|
|
Clients: Pharmaceutical industry |
Fin.Dir.-CFO: |
www.epixis.com |
|
Age: 17 year(s) |
BusDev: |
|
|
|
Financers (Hist.): Génopole 1er Jour |
ERYtech Pharma |
2004 |
Rhône-Alpes |
Delivery, Drugs |
Personal venture | |
Cancers |
Clinical |
|
Lyon |
Key words: Encapsulation, Red blood cells, Cancer, Cleav’Ery, Oxygen’Ery, Deliv’Ery, Vaccin’Ery, Graspa |
Managing Dir.-CEO: Beyen (Gil) [M.Sc. Bioengineering (Belgium), MBA, ex-TiGenix, Arthur D. Little] and Goineau (Pierre-Olivier) [co-founder, born 1967, MBA IAE Lyon, ex-KPMG] |
|
|
Mission: to develop the encapsulation of therapeutic molecules or enzymes into red blood cells in order to improve the therapeutic index, notably in orphan indications or underserved subpopulation of higher risk patients |
Oper.Dir.: |
|
|
Clients: Prescribers |
Sc.Dir.-CSO: Godfrain (Yann) [co-founder, born 1970, Ph.D., Biomedical Eng., ex-BioAlliance Pharma, Hemosystem, Hemoxymed] |
www.erytech.com |
|
Age: 16 year(s) |
Pharm.Dir.: Bailly (David) [Pharm.Dr, Chem.Eng. (Montréal), ex-Skyepharma, Aguettant] |
|
|
|
Fin.Dir.-CFO: |
|
|
|
BusDev: Bouvier (Maud) [Sup de Co (Grenoble)] |
|
|
|
Financers (Hist.): AXA P.E., Auriga Partners, AGF P.E., Capdecisif, Créalys, Idinvest |
Eye Tech Care |
2008 |
Rhône-Alpes |
Development, Devices |
Personal venture | |
Ophtalmology |
Trade |
|
Rillieux la Pape (near Lyon) |
Key words: Ultra-sounds, Ophthalmology, Glaucoma, EYEOP1 |
Managing Dir.-CEO: Romano (Fabrizio) [co-founder, born 1962, Vet.D., ex-Edap TMS] |
|
|
Mission: to develop a proprietary ultrasound-based procedure for treating eye diseases |
Clin.Dir.: Farcy (Laurent) [co-founder, born 1973, Ms. biochemistry, ex-Medicrea, Sofradim] |
|
|
Clients: undisclosed |
Indus.Dir.: Chapuis (Philippe) [co-founder, born 1968, Eng. ESEM Orléans, IAE, ex-Edap TMS] |
www.eyetechcare.com |
|
Age: 12 year(s) |
Fin.Dir.-CFO: |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): Crédit Agricole, CEA Valorisation, SHAM |
Flamel Technologies |
1990 |
Rhône-Alpes |
Delivery, Drugs |
Start-up | |
Multiple |
Trade |
|
Venissieux |
(also, Design, Devices) |
Managing Dir.-CEO: Anderson (Michael S.) [ex-Éclat Pharmaceuticals, KV Pharmaceutical, Ther-Rx Corporation, Schein, A.H. Robins Company] |
|
(near Lyon) |
Key words: Polymer encapsulation, Interferon, Micropump, Medusa, Drug-protein delivery, Long Action |
Sc.Dir.-CSO: Meyrueix (Rémi) [Ph.D., Eng. Physics, ex-Rhône Poulenc Santé] & Castan (Catherine) [Ph.D.] |
|
|
Mission: to improve the therapeutic characteristics, safety profile and ease of use of a wide variety of existing drugs, by using proprietary drug delivery platforms, Medusa for therapeutic proteins and peptides and Micropump for small molecules, with expertise in polymer chemistry |
Oper.Dir.-COO: Jorda (Raphaël) [Ph.D., Eng. chemistry, ex-Rhône Poulenc Santé] |
www.flamel.com |
|
Clients: Pharmaceutical industry (own development up to pre-registration), Agrochemical industry |
Fin.Dir.-CFO: Crouzet (Siân) [ex-McCormik, Ernst & Young] |
|
|
Age: 30 year(s) |
BusDev: Lisi (Steven A.) [ex-Deerfield Mgt, Panacea Asset Mgt, Millenium Partners] |
|
|
|
Strat.Comm.Dir.: Mosseri Marlio (Charles) |
|
|
|
Financers (Hist.): Public (Nasdaq) |
Fluofarma |
2003 |
Aquitaine |
Contract, Research (also, Contract, Services) |
Spin-off | |
Multiple |
Subcontractor |
|
Bordeaux |
Key words: High Content Screening (HCS), Automated flow cytometry, Cell-based assays |
Managing Dir.-CEO: Pin (Jean-Baptiste) [founder, born 1974, ex-Ernst & Young Biotechnology] |
|
|
Mission: to provide third parties with High Content Screening (in-cellulo screening) services for target and drug discovery, predictive toxicity testing and cosmetics development |
Sc.Dir.-CSO: Ichas (François) [Ph.D. biomedical sciences, ex-Inserm] |
|
|
Clients: Pharmaceutical industry, Biotech, Cosmetic industry |
Sales&Mktg.Dir.: Plane (Julie) [ex-Avenium Consulting] |
www.fluofarma.com |
|
Age: 17 year(s) |
Fin.Dir.-CFO: |
|
|
|
BusDev: Brisson (Bruno) [ex-Cellectis, Mauna Kea Technologies, Biospace Lab] |
|
|
|
Financers (Hist.): privately owned (registered capital 2006 = 0.24 M€) |
GemacBio |
1999 |
Aquitaine |
Development, Diagnostics |
Personal venture | |
CNS |
Trade |
|
Berganton, Saint Jean d’Illac |
(also, Contract, Manufacturing) |
Managing Dir.-CEO: Lurton (Louis) [born 1956] |
|
(near Bordeaux) |
Key words: Antibodies, Customization, CNS disorders, Auto-immune diseases |
Sc.Dir.-CSO: |
|
|
Mission: to develop a wide range of monoclonal and polyclonal antibodies against neurotransmitters, nitrosylated and nitrated amino-acids, bacterial antigens |
Fin.Dir.-CFO: |
www.gemacbio.com |
|
Clients: Distributors, Pharmaceutical industry, Biotech, Research labs |
BusDev: |
|
|
Age: 21 year(s) |
Financers (Hist.): IRDI, ACI, SOCRI, Oséo/Anvar, business angels |
|
|
|
Note: the company website has ceased to provide with news since Fall 2009 |
Genepep |
2003 |
Midi-Pyrénées |
Contract, Research |
Personal venture | |
Multiple |
Preclin |
|
St Jean de Védas |
(also, Discovery, Drugs) |
Managing Dir.-CEO: Puget (Karine) [co-founder, born 1970, Ph.D., ex-CNRS] |
|
(near Montpellier) |
Key words: Peptides, Transcriptomes, Bio-informatics softwares |
Sc.Dir.-CSO: Puget (Karine) |
|
|
Mission: to provide third parties with custom peptide synthesis, antibody production, peptide and protein sequencing, mass spectrometry, and to design own peptides for therapeutic research |
Fin.Dir.-CFO: Chorro (Karine) [HEC (1994), also Deputy CEO] |
www.genepep.com |
|
Clients: Pharmaceutical industry (own development up to proof of concept) |
BusDev: |
|
|
Age: 17 year(s) |
Financers (Hist.): Sud Angels |
Genewave |
2001 |
IDF |
Design, Devices |
Personal venture | |
Multiple |
Trade |
|
Paris |
Key words: Automated real-time micro-array, Hybridization imaging systems, Low-cost micro-array readers, HybLive |
President: Desforges (François-Xavier) [born 1960, Ph.D. Electronics, ex-Photonetics] |
|
|
Mission: to develop, manufacture and market cutting-edge microarray instrumentation for diagnostic, clinical and life science research |
Managing Dir.-CEO: Choumane (Houtaï) [Ph.D. Optics, also co-CEO] |
|
|
Clients: Research labs, Biotech, Other Institutions, OEM markets |
Sc.Dir.-CSO: Weisbuch (Claude) [co-founder, born 1945, Ph.D. physics, Normale Sup, CNRS, University Professor (USA), ex-Bell Laboratories, Saint-Gobain, Thomson-CSF] |
www.genewave.com |
|
Age: 19 year(s) |
Tech.Dir.-CTO: Rattier (Maxime) [Ph.D., Polytechnique, ex-Luxtera] |
|
|
|
Dev.Dir.: Marcy (Yann) [Ph.D., biological physics (Institut Curie)] |
|
|
|
Fin.Dir.-CFO: |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): |
|
|
|
Note: no legal accounting report since 2006, website contents much reduced in October 2012 (e.g. no more news) |
Genfit |
1999 |
North-Picardie |
Discovery, Drugs |
Start-up | |
Cardiovasc |
Clinical |
|
Lille |
Key words: Cardiometabolic diseases, Dyslipidemia, Diabetes |
Managing Dir.-CEO: Mouney (Jean-François) [co-founder, born 1955, Sup de Co (Paris), ex-M&M, also chairman] |
|
|
Mission: to bring therapeutic and diagnostic solutions to combat the major health concerns of diabetes, its associated risk factors, and its complications |
Oper.Dir.-COO: Darteil (Raphaël) [Ph.D. molecular and cellular biology, ex-Aventis] |
|
|
Clients: Pharmaceutical industry |
Sc.Dir.-CSO: |
www.genfit.com |
|
Age: 21 year(s) |
Fin.Dir.-CFO: Huitorel (Nathalie) [Sup de Co (Lille), ex-MS Composites, Finuchem] |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): Finorpa, Nord Cration, BP Création, Ya Global, University Lille II, Public |
Genomic Vision |
2004 |
IDF |
Discovery, Drugs |
Personal venture | |
Multiple |
Launch |
|
Paris |
(also, Discovery, Diagnostics) |
Managing Dir.-CEO: Bensimon (Aaron) [born 1957, co-founder, Ph.D. molecular biology, ex-Institut Pasteur] |
|
|
Key words: Diagnostics, Nanotechnology, DNA, Molecular combing |
Sc.Dir.-CSO: Conseiller (Emmanuel) [Ph.D., ex-Sanofi-Aventis, Rhône-Poulenc Rorer] |
|
|
Mission: to develop novel diagnostic, biomarkers and drug discovery solutions based on proprietary nanotechnology for DNA analysis in the areas of cancer and acute diseases |
Oper.Dir.-COO: Nerson (Daniel) [born 1958, co-founder, Ph.D., ex-Pasteur Mediavita, Dade-Behring] |
www.genomicvision.com |
|
Clients: Pharmaceutical industry (Sanofi-Aventis), Biotechs |
Fin.Dir.-CFO: Martin (Erwan) [ex-Cytomics (co-founder), Syndex, Université de Marne la Vallée (Professeur, finances)] |
|
|
Age: 16 year(s) |
BusDev: Abut (Fadilha) |
|
|
|
Financers (Hist.): Société Générale Asset Management Alternative Investments (SGAM AI), Vesalius BioCapital |
GenoSafe |
2003 |
IDF |
Contract, Services |
Start-up | |
Multiple |
Subcontractor |
|
Évry |
Key words: Bio-therapeutics, Drug evaluation |
Managing Dir.-CEO: Roques (Stéphane) [born 1972, SupdeCo, ex-Arthur Andersen, AFM, Genethon] |
|
(near Paris) |
Mission: to evaluate the efficacy and safety of biotherapeutic products (viral and non-viral vectors, vaccines, recombinant proteins, monoclonal antibodies, cellular products …), for third parties |
Sc.Dir.-CSO: Audit (Muriel) [Ph.D. Biology, ex-Genethon] |
|
|
Clients: Pharmaceutical industry, Biotechs, Research labs |
Fin.Dir.-CFO: |
www.genosafe.com |
|
Age: 17 year(s) |
BusDev: Zuliani (Vincent) [Ms. microbiology, ex-Genethon] |
|
|
|
Financers (Hist.): A2I (seed), Genethon, AFM |
GenoScience Pharma |
2001 |
Méditerranée |
Discovery, Drugs |
Personal venture | |
Virus |
Preclin |
|
Marseille |
(also, Contract, Research) |
Managing Dir.-CEO: (interim) Halfon (Philippe) [founder, born 1960, M.D., Ph.D., Alphabio (CEO)] |
|
|
Key words: Antivirals, Protease inhibitor, HCV |
Sc.Dir.-CSO: Benech (Philippe) [Ph.D., ex-CNRS, founder Genesodi] |
|
|
Mission: to discover, develop and commercialize novel antiviral products (combining internal expertise in viral infections and unique molecular modeling through GenMol proprietary software (current focus on compounds for the treatment of hepatitis C infections) |
Tech.Dir.-CTO: Pépé (Gérard) [Ph.D., Research Director (CNRS)] |
www.3dgenoscience.com |
|
Clients: undisclosed |
Fin.Dir.-CFO: Corroy (Jean-Paul) [Sup de Co, ex-Alphabio] |
|
|
Age: 19 year(s) |
BusDev: |
|
|
|
Financers (Hist.): |
|
|
|
Notes : no news on website since 2005 and URL changed from genosciencepharma.com back to old 3dgenoscience.com in 2011 ; legal data show a loss in capital in July 2011 (recurrent) |
Genoscreen |
2001 |
North-Picardie |
Contract, Research |
Spin-off | |
Genome |
Subcontractor |
|
Lille |
Key words: DNA, Genome, Sequencing, Genotyping, Mutation detection, Gene expression, Microbial identification, Microbial typing |
Managing Dir.-CEO: Tordeux (André) [born 1947] |
|
|
Mission: to develop and to realize innovative services on all kind of genomes to provide answers that best suit the needs of research laboratories, by using own high throughput equipments |
Sc.Dir.-CSO: Tordeux (André), also Ferreira (Stéphanie) [Ph.D.] |
|
|
Clients: Pharmaceutical industry, Research labs, Life science industries, Academic research institutions |
Sales Dir.: Antigny (Frédéric) [M.Sc., MBA] |
www.genoscreen.fr |
|
Age: 20 year(s) |
Fin.Dir.-CFO: |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): privately owned |
GenOway |
1999 |
Rhône-Alpes |
Contract, Research |
Spin-off | |
Genome |
Subcontractor |
|
Lyon |
Key words: Gene amplification, Clonal animal, Mouse, Toxicology tests |
Managing Dir.-CEO: Fraichard (Alexandre) [co-founder, born 1968, Ph.D. molecular biology (1997), Normale Sup (Lyon), MBA (HEC)] |
|
|
Mission: to provide third parties with customized and ready-to-use genetically modified mouse and rat models (Knock-out, conditional Knock-out, Knock-in, RNAi, humanized, transgenic mice and rats) |
Sc.Dir.-CSO: |
|
|
Clients: Research labs |
Fin.Dir.-CFO: de Poncins (Gilles) [co-founder, Science Po (Paris), MBA, ex-Renault, Qualis, Sofecome] |
www.genoway.com |
|
Age: 21 year(s) |
BusDev: Thiam (Kader) |
|
|
|
Financers (Hist.): Dassault Développement, CDC E.I., Finoway (Qualis), Rhône Alpes Création, Public |
Genticel |
2001 |
Midi-Pyrénées |
Discovery, Immunology |
Spin-off | |
Vaccines |
Clinical |
|
Labège |
Key words: Therapeutic vaccines, HPV, Cancer, Viral and bacterial infections, ProCervix |
Managing Dir.-CEO: Timmerman (Ben) [founder, born 1959, Ph.D. Molecular Genetics, MBA, ex-Novartis Agro, Procordia] |
|
(near Toulouse) |
Mission: to develop immuno-therapeutic products for the treatment of infection, neoplasia and cervical cancer, caused by Human Papillomavirus (HPV) |
Sc.Dir.-CSO: Bissery (Marie-Christine) [Ph.D., Pharm.D., ex-Sanofi–Aventis, Rhône-Poulenc] |
|
|
Clients: Prescribers |
Fin.Dir.-CFO: Koch (Martin) [Eng., MBA, ex-Eli Lilly, Cap Gemini, Elan, Zeneus, Cephalon] |
www.genticel.com |
|
Age: 19 year(s) |
BusDev: |
|
|
|
Financers (Hist.): Institut Pasteur, FAM-Midi-Pyrénées, Edmond de Rothschild Investment Partners, IRDI, Amundi Private Equity Funds, InnoBio, FSI |
|
|
|
Note : from inception to February 2010, the company name has been BT Pharma (BT for Benedikt Timmerman, Founder) |
GTP Technology |
2000 |
Midi-Pyrénées |
Contract, Manufacturing |
Spin-off | |
Multiple |
Subcontractor |
|
Labège |
(also, Design, Drugs) |
Managing Dir.-CEO: Pease (Christopher) [born 1963, M.Sc. Insa (Lyon), ex-Millipore], also Managing dir. Darlington Life Science |
|
(near Toulouse) |
Key words: In-vitro protein production, Gene work, Eiffel biostructure, L-lactis, Sensorines, Therapeutic protein, Cancers |
Sc.Dir.-CSO: Ginisty (Hervé) [born 1971, Ph.D. molecular biology] |
|
|
Mission: to provide third parties with taylor-made solutions for the engineering and expression of recombinant proteins, and, to undertake own research on the L.lactis system for therapeutic proteins production |
Oper.Dir.-COO: Devic (Éric) [founder, born 1966, Pharm.D., Ph.D. molecular biology], also chairman |
www.gtptech.com |
|
Clients: Pharma industry, Biotechs, Research labs |
Tech.Dir.-CTO: Mozo (Julien) [Ph.D.] |
|
|
Age: 20 year(s) |
Fin.Dir.-CFO: |
|
|
|
BusDev: Hountondji (Séverine) [M.Sc. Insa] |
|
|
|
Financers (Hist.): privately owned, undisclosed |
Helios Biosciences |
2002 |
IDF |
Discovery, Targets (also, Contract, Research) |
Academic | |
Cancers |
Preclin |
|
Romainville |
Key words: Tissue expression, InSitu Hybridization, Biomarkers, Prostate cancer, Epilepsy, SIMPathway |
Managing Dir.-CEO: Dumas (Jean-Baptiste) [founder, born 1958, Ph.D., ex-Genset, Genethon] |
|
(near Paris) |
Mission: to research for own pipeline or to provide third parties with proprietary tools in the identification and characterization of therapeutic targets and biomarkers |
Sc.Dir.-CSO: Dumas (Sylvie) [Ph.D., Normale Sup, ex-CNRS] |
|
|
Clients: Research labs, Cosmetic and Pharma industries |
Fin.Dir.-CFO: |
www.helios-bioscience.com |
|
Age: 18 year(s) |
Med.Dir.-CMO: Vujasinovic (Todor) [M.D., ex-CNRS] |
|
|
|
Financers (Hist.): privately owned (registered capital 2006 = 0.15 M€) |
|
|
|
Notes: no legal accounting report since 2006 ; the company is facing legal redress since September 12. 2012 ; URL has changed in 2012 from www.helios-biosciences.com to www.helios-bioscience.com (without ‘s’) |
Hemarina |
2007 |
Bretagne |
Discovery, Drugs |
Spin-off | |
Blood |
Preclin |
|
Morlaix |
Key words: Hemoglobin, Blood-transfers, Transfusion, Sea-Invertebrate, Arenicole |
Managing Dir.-CEO: Zal (Franck) [co-founder, born 1966, Ph.D. oceanography, ex-CNRS] |
|
|
Mission: to develop a new generation of oxygen-carrier for therapeutical and industrial applications (to help cope with the huge deficit of blood worldwide), based on extraction and purification from a marine organism |
Sc.Dir.-CSO: Zal (Franck) |
|
|
Clients: Pharmaceutical industry (developement limited to early stage), Biotechs |
Techn.Dir.-CTO: Rousselot (Morgane), [co-founder, Ph.D., Eng. ENSCMu, ex-GSK] |
www.hemarina.com |
|
Age: 13 year(s) |
Pharm.Dir.: Naccache (Alain) [Pharm.Dr] |
|
|
|
Fin.Dir.-CFO: |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): privately-owned, Inserm Transfert Initiative, Synergie Finance, Vaneau, and various business angels (registered capital 2007 = 0.26 M€) |
Hybrigenics |
1998 |
IDF |
Discovery, Drugs |
Academic | |
Cancers |
Preclin |
|
Paris |
(also, Services, Research) |
Managing Dir.-CEO: Delansorne (Rémi) [born 1959, Vet.D., Ph.D., ex-Theramex (Merck KgAa)] |
|
|
Key words: Protein-protein interaction, Cancer, Inecalcitol, D-vitamin, Protease inhibitor, Protein-interactions maps (PIMs), Ubiquitin |
Oper.Dir.-COO: Formstecher (Etienne) [Polytechnique, Ph.D., also deputy CEO] |
|
|
Mission: to develop internal R&D programs on innovative target and therapeutics against cancer and to market proprietary high throughput technology and bioinformatics platforms focused on identification, validation and inhibition of protein interactions |
Tech.Dir.: Rain (Jean-Christophe) [Ph.D. Molecular Genetics, co-founder, also deputy CEO] |
www.hybrigenics-services.com |
|
Clients: Prescribers |
I.T.Dir.-CIO: Collura (Vincent) [Ph.D. structural bioinformatics] |
|
|
Age: 23 year(s) |
Financers (Hist.): Medicis, Rendex, Sofindev, IMH, Lombard Odier, Alafi Capital, Life Science Partners, Banexi V.P., C.F. Edmond de Rothschild, Public |
|
|
|
note : in September 2012, the company changes its URL from www.hybrigenics.com to www.hybrigenics-services.com |
Hyphen BioMed |
1999 |
IDF |
Design, Diagnostics |
Personal venture | |
Cardiovasc |
Trade |
|
Neuville-sur-Oise |
(also, Discovery, Diagnostics) |
Managing Dir.-CEO: Amiral (Jean) [born 1952, Ph.D., Immunologist, Biochemist, ex-Serbio Stago (CSO)] |
|
(near Paris) |
Key words: Research reagents, Thrombosis, Haemostasis, Auto-Immunity, Zymutest |
Sc.Dir.-CSO: Vissac (Anne Marie) [born 1956, ex-Project Leader Serbio Stago] |
|
|
Mission: to develop a full line of innovative kits in diagnostic and research reagents and biochemicals, manual or automated, designed with clotting, chromogenic or immunological methods, for the exploration of Thrombosis, Haemostasis, Fibrinolysis and Auto-Immunity |
Fin.Dir.-CFO: |
www.hyphen-biomed.com |
|
Clients: Research labs, Pharmaceutical industry |
BusDev (& sales): Penissard (Véronique) |
|
|
Age: 21 year(s) |
Financers (Hist.): privately owned, IDF Développement, Banque Populaire |
Imagene |
1998 |
Aquitaine |
Contract, Manufacturing |
Personal venture | |
Genome |
Trade |
|
Pessac |
Key words: DNA-conservation, Encapsulation, Extraction |
Managing Dir.-CEO: Tuffet (Sophie) [founder, Ph.D. biology] |
|
(near Bordeaux) |
Mission: to provide third parties with high quality, long term preservation of DNA at room temperature for large scale genomic resources banks |
Sc.Dir.-CSO: |
|
|
Clients: Research labs |
Fin.Dir.-CFO: |
www.imagene.fr |
|
Age: 22 year(s) |
BusDev: |
|
|
|
Financers (Hist.): OTC A.M. and Aquitaine Création Investissement |
ImmunId |
2005 |
Rhône-Alpes |
Contract, Research |
Personal venture | |
Multiple |
Trade |
|
Grenoble |
Key words: Personalized diagnostics, Combinatorial Repertoire analysis, Immunology analysis, Immunodeficiency, Immuno-monitoring, T & B cell repertoire, Genomic DNA, Infectious diseases, Auto-immune diseases, Blood cancers, Lymphoma and Leukemia diagnosis, ImmunTracker, ImmunIg |
Managing Dir.-CEO: Pasqual (Nicolas) [co-founder, born 1977, Ph.D. molecular biology, ex-CEA] |
|
|
Mission: to provide third parties with innovative diagnostic and prognostic tools and high value-added services to decrease clinical study costs by selecting better immuno-drug candidates and by measuring immuno-reconstitution and suppression kinetics |
Sc.Dir.-CSO: Pasqual (Nicolas) |
|
|
Clients: Research labs, Hospitals, Pharmaceutical industry |
Oper.Dir.-COO: Weisbuch (Sébastien) [born 1977, Ph.D. nanobiology, ex-CEA] |
www.immunid.com |
|
Age: 15 year(s) |
Tech.Dir.-CTO: Mouret (Jean-François) [Pharm.D., ex-Applied Biosystems, Cogenics, Genome Express (co-founder)] |
|
|
|
Fin.Dir.-CFO: |
|
|
|
BusDev: Plantier (Nadia) |
|
|
|
Financers (Hist.): privately owned (registered capital 2006 = 0.053 M€) |
|
|
|
Note : website revamped in March 2009 |
Immutep |
2001 |
IDF |
Discovery, Immunology |
Spin-off | |
Cancers |
Clinical |
|
Orsay |
(also, Discovery, Diagnostics) |
Managing Dir.-CEO: Hawken (John B.) [co-founder, born 1948, Ms. chemistry (Oxford), MBA, ex-Diatos, EntoMed, Neurotech, Aptanomics, Shell] |
|
(near Paris) |
Key words: Cancer, Chronic Infectious Diseases, T Cell Immune responses, Immuno-therapy, MABs, Vaccines, Lag-3 protein |
Sc.Dir.-CSO: Triebel (Frédéric) [co-founder, born 1954, M.D., Ph.D. immunology, ex-Inserm, Prof. Immunology, Paris University, Institut Gustave Roussy (IGR)] |
|
|
Mission: to develop immunostimulatory factors for the treatment of cancer and chronic infectious diseases and immunomodulatory therapeutic antibodies for the treatment of cancers or autoimmune diseases |
Fin.Dir.-CFO: |
www.immutep.com |
|
Clients: Prescribers |
BusDev: |
|
|
Age: 19 year(s) |
Financers (Hist.): Innoven Partenaires, H2I |
Imstar |
1985 |
IDF |
Contract, Services |
Spin-off | |
Studies |
Subcontractor |
|
Paris |
Key words: Microscopic imaging, Cell screening, Systems, Instruments, High throughput, Pathfinder |
Managing Dir.-CEO: Soussaline (Françoise) [born 1945] |
|
|
Mission: to provide third parties with complete vertical solutions for fully automated high-throughput cellular analysis, in the fields of genotoxicity and environmental toxicity, focused on compound screening, biomonitoring, cytopathology, and dedicated to research, diagnostic, staging and drug discovery |
Sc.Dir.-CSO: Soussaline (Françoise) |
|
|
Clients: Research labs |
Fin.Dir.-CFO: |
www.imstar.fr |
|
Age: 35 year(s) |
BusDev: |
|
|
|
Financers (Hist.): privately owned |
In-Cell-Art |
2005 |
Bretagne |
Design, Delivery |
Personal venture | |
Multiple |
Preclin |
|
Nantes |
(also Discovery, Drugs) |
Managing Dir.-CEO: Peyrot (Alain) [ex-Pharmacia, Sanofi, Mérieux, Wellcome, Wyeth] |
|
|
Key words: Supramolecular nanocarriers, Intracellular delivery, Polypeptide deficiencies, siRNA therapeutics, DNA vaccines, Antibodies production, In vitro transfection |
Sc.Dir.-CSO: Pitard (Bruno) [co-founder, Ph.D., ex-Aventis Pasteur, Rhône Poulenc Rorer, CNRS, Inserm] |
|
|
Mission: to ascertain the delivery of a drug to the heart of the cell, the prolongation of its bioavailability, the vectorisation of DNA or RNA-based active principles |
Oper.Dir.-COO: Belloc (Chloé) [born 1977, Ph.D., MBA] |
www.incellart.com |
|
Clients: Pharmaceutical industry, Biotechs, Academic labs |
Fin.Dir.-CFO: |
|
|
Age: 15 year(s) |
BusDev: |
|
|
|
Financers (Hist.): privately owned (registered capital 2006 = 0.05 M€) |
Indicia Biotechnology |
1998 |
Rhône-Alpes |
Contract, Research |
Personal venture | |
Studies |
Subcontractor |
|
Lyon |
Key words: Microparticle technology, Immunoassay, Reagents, Luminex, OEM dosing methods, OEM production services |
Managing Dir.-CEO: Legastelois (Stéphane) [born 1960, Ph.D. biochemistry, ex-Merck KgAa, Indicia Diagnostics] |
|
|
Mission: to provide third parties with solutions in R&D and manufacturing by providing a complete range of comprehensive services in the areas of immuno-diagnostics, microbiology and sterile reagents |
Oper.Dir.-COO: Panier (Elodie) [Ms.Sc., Eng. IUP, DESS Management] |
|
|
Clients: Pharmaceutical industry, Diagnostics industry |
Fin.Dir.-CFO: |
www.indicia.fr |
|
Age: 22 year(s) |
BusDev: |
|
|
|
Financers (Hist.): privately owned (registered capital 2010 = 0.51 M€) |
|
|
|
Note : initial company registering under Indicia: 1984.03 |
InGen Biosciences |
2001 |
IDF |
Design, Diagnostics |
Start-up | |
Infections |
Trade |
|
Chilly-Mazarin |
Key words: Serology, In-vitro, Biomarkers, Infectious diseases, Bacterial antigens, Microbiology, Non-invasive testing, Capucine, Abag |
Managing Dir.-CEO: Buckle (Isabelle) [Ph.D. microbiology, ex-Applied Biosystems, Ciphergen Biosystems, Amersham Pharmacia Biotech] |
|
(near Paris) |
Mission: to design and manufacture protein biomarkers for multiparametric diagnostic in infectious diseases |
Sc.Dir.-CSO: Mignon Godefroy (Karine) [Ph.D, ex-Chemunex, BMD, Bio-Rad] |
|
|
Clients: Pharmaceutical industry |
Oper.Dir.-COO: Mollet (Patrick) [ex-Organon] |
www.ingen.fr |
|
Age: 19 year(s) |
Mktg.Dir.: Martin (Jacques) [Eng. ESITPA, ex-Clonatec] |
|
|
|
Fin.Dir.-CFO: Elorga (Esteban) [Sup-de-Co, ex-Arhur Andersen] |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): Innoven Partners, Société Générale A.M. |
|
|
|
Notes : Ingen website, acquired in 2006, updated with Ingen Biosciences (no company website ever as Abag) ; the company is subject of a take over in Novemebr 2012 |
Innate Pharma |
1999 |
Méditerranée |
Discovery, Drugs |
Start-up | |
Cancers |
Clinical |
|
Marseille |
Key words: Immuno-therapy, Immuno-modulators, Toll-like receptors (TLR), Cancer, IPH 4201 |
Managing Dir.-CEO: Brailly (Hervé) [co-founder, born 1961, Ph.D., ex-Immunotech-Beckman-Coulter] |
|
|
Mission: to develop first in class drugs targeting the innate immune system |
Sc.Dir.-CSO: Romagné (François) [Ph.D., co-founder, ex-Immunotech-Beckman-Coulter] |
|
|
Clients: Prescribers |
Clin.Dir.-CMO: Rozencweig (Marcel) [M.D., ex-BMS] |
www.innate-pharma.com |
|
Age: 21 year(s) |
Fin.Dir.-CFO: Moukheibir (Catherine) [MBA, ex-Zeltia, Shire, Movetis] |
|
|
|
BusDev: Morel (Yannis) [Ph.D. oncology, NormalSup] |
|
|
|
Financers (Hist.): Sofinnova Partners, Auriga Partners, GIMV, Alta Partners, Gilde Biotech & Nutrition, Pechel Industries, Innoveris, Quilvest, NIF Ventures, Novo-Nordisk, Public |
InnaVirVax |
2008 |
IDF |
Discovery, Immunology |
Start-up | |
HIV |
Clinical |
|
Évry |
(also, Discovery, Diagnostics) |
Managing Dir.-CEO: Crouzet (Joël) [born 1958, Ph.D., Eng. Agro (Grignon), ex-Eurobiobiz, Inserm Transfert, Neurotech, APCells, Rhône-Poulenc Rorer] |
|
(near Paris) |
Key words: HIV, CD4 restoration, Predictive test |
Sc.Dir.-CSO: Crouzet (Joël) |
|
|
Mission: to develop a new HIV therapeutic vaccine aiming to restore CD4 to normal levels (without immunodeficiency) and to design a diagnostics test able to predict the evolution of the AIDS pathology of a given patient |
Fin.Dir.-CFO: |
www.innavirvax.fr |
|
Clients: Pharmaceutical industry |
Proj.Mgr.: Ho Tsong Fang (Raphaël) [Vet.D., Ph.D. microbiology and medical virology, ex-Institut Pasteur, UCLA (Los Angeles)] |
|
|
Age: 12 year(s) |
Financers (Hist.): Pradeyrol Développement, Fa Dièse, CapDecisif Management, Genopole 1er Jour |
Innovative Health Diagnostics |
2009 |
Alsace |
Discovery, Diagnostics (also, Contract, Research) |
Personal venture | |
Alzheimer, |
Preclin |
|
Strasbourg |
Key words: Alzheimer, Biomarkers, DiagAlz |
Managing Dir.-CEO: Regnaut (Xavier) [co-founder, born 1964, Eng. Agro, Ms. Genetics, EMBA HEC] |
|
|
Mission: to develop and sell diagnostic solutions in the field of neurodegenerative diseases, based on detection of specific biological blood markers |
Sc.Dir.-CSO: de Barry (Jean) [co-founder, Ph.D., Eng. Chemistry, ex-Inserm) |
|
|
Clients: Prescribers, Hospitals |
Clin.Dir.-CMO: Sellal (François) [co-founder, M.D., Pharm.D., ex-CM2R] |
www.ihdiag.com |
|
Age: 11 year(s) |
Fin.Dir.-CFO: |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): privately owned (registered capital 2009 = 0.05 M€), Oseo, FEDER, Sodiv Alsace |
|
|
|
Note : IHD is the trade mark company name |
IntegraGen |
2000 |
IDF |
Discovery, Diagnostics |
Spin-off | |
Cardiovasc |
Launch |
|
Évry |
Key words: Genes, Genomic mutations, Diabetes, Obesity, Bipolar disorders, Schizophrenia, Autism, GenomeHIP |
Managing Dir.-CEO: Courtieu (Bernard) [born 1964, Vet.D., MBA, ex-Gemini Conseil, Ariba] |
|
(near Paris) |
Mission: to research in gene targets and to market molecular diagnostics products and services that provide clinicians with new tools of personalized diagnosis, treatment, and therapy |
Sc.Dir.-CSO: Liebaert (François) [MBA, ex-Schering, Abbott] |
|
|
Clients: Prescribers |
Fin.Dir.-CFO: Riot-Lamotte (Laurence) [CESEM, ex-Aureus-Pharma, Deloitte & Touche, Thomson, Deutsche Telekom France] |
www.integragen.com |
|
Age: 20 year(s) |
SalesMktg: Martin (Emmanuel) [Pharm.D., ex-Applied Biosystems] |
|
|
|
BusDev: Brady (David) [MBA, ex-Biogen-Idec, Lonza] |
|
|
|
Financers (Hist.): CDC Innovation, GenAvent, Bioam, Bay Tech, AGF P.E., Société Générale A.M., DSM |
Ipsogen |
1999 |
Méditerranée |
Discovery, Diagnostics |
Personal venture | |
Cancers |
Trade |
|
Marseille |
Key words: Assays, Molecular expression, Biomarker, Blood cancer, Leukemia |
Managing Dir.-CEO: Fert (Vincent) [co-founder, born 1959, Ms. immunology, ex-Immunotech, Beckman Coulter] |
|
|
Mission: to design, manufacture and market molecular assays with proven expertise in identifying and translating key discoveries into essential tests intented to support personalized approach to cancer treatment |
Sc.Dir.-CSO: Hermitte (Fabienne) [co-founder, Ph.D., INA, ex-Rhône Poulenc, CNRS] |
|
|
Clients: Research labs, Prescribers |
Oper.Dir.-COO: Debono (Stéphane) [born 1975, ESIM, ex-Immunotech, Beckman Coulter] |
www.ipsogen.com |
|
Age: 21 year(s) |
Med.Dir.-CMO: Peyro-Saint-Paul (Hélène) [M.D. (Neurology), MBA (Essec), ex-B.M.S., Actelion, Serono] |
|
|
|
Fin.Dir.-CFO: Boissel (Pascale) [HEC, ex-Price Waterhouse Coopers, Danone, Lafarge] |
|
|
|
SalesMktg: Danan (Corinne) [ISC, MBA (Insead, 1990), ex-Monogram Biosciences, Eli Lilly] |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): Samenar (Caisse d’Epargne), Institut Paoli-Calmettes, Société Générale A.M., Matignon Technologies, Innovéris, Connecticut Innovations, Viveris, Natixis, Octalia, Public |
|
|
|
Note : trade mark logo : «Ipsogen, cancer profiler» |
I-Stem |
2004 |
IDF |
Discovery, Drugs |
Start-up | |
Multiple |
Incub |
|
Évry |
(also, Contract, Research) |
Managing Dir.-CEO: Peschanski (Marc) |
|
(near Paris) |
Key words: Stem cells, Monogenic diseases, Drug Discovery, Cell therapy, Pathological modelling, HTS & HCS |
Sc.Dir.-CSO: Peschanski (Marc) |
|
|
Mission: to develop new treatments based on the potential offered by pluripotent stem cells (human embryonic cells and iPS) and applicable to rare diseases of genetic origin |
Fin.Dir.-CFO: Zakhia (Raymond) |
www.istem.eu |
|
Clients: undisclosed |
BusDev: Duprat (Sébastien) [born 1975, D.E.A. Biology, ex-ESTOOLS, Scientific Research Helsinki-Lille] |
|
|
Age: 16 year(s) |
Financers (Hist.): INSERM, AFM (French Muscular Dystrophy Association) |
|
|
|
Note : a public-private Institute equally funded by INSERM and AFM, on a yearly budget (about 7 M€ each year between 2005 and 2008) |
Karcinolys |
2005 |
Rhône-Alpes |
Development, Drugs |
Start-up | |
Cancers |
Incub |
|
Lyon |
Key words: Biologicals, Liver cancer, Pancreatic cancer, Herpes virus |
Managing Dir.-CEO: Béjot (Jean-Luc) [born 1957, M.D., ex-OPI, Novartis, Quintiles, Genzyme, Ipsen, Cassenne] |
|
|
Mission: to develop a new generation of tumour-selective «replication conditional» HSV-1 derived oncolytic viruses |
Sc.Dir.-CSO: |
|
|
Clients: Pharmaceutical industry |
Fin.Dir.-CFO: |
www.no-website.net |
|
Age: 15 year(s) |
BusDev: |
|
|
|
Financers (Hist.): privately owned (registered capital 2009 = 0.1 M€) |
|
|
|
Communication : no website, yet |
Keosys |
2001 |
Bretagne |
Development, Devices |
Start-up | |
Cancers |
Trade |
|
Saint Herblay (near Nantes) |
Key words: Nuclear medicine, Digital imaging, Radiology, Mammography, I.T. programmes, Visio+, Positoscope |
Managing Dir.-CEO: Fortineau (Jérôme) [born 1968, co-founder, Eng., ex-Alcatel] |
|
|
Mission: to develop new imaging and communication systems for nuclear medicine and radiology |
Sc.Dir.-CSO: Terve (Pierre) |
|
|
Clients: Distributors or directly to Hospitals, Clinics, Cancer centers, Radiologists |
Fin.Dir.-CFO: |
www.keosys.com |
|
Age: 20 year(s) |
BusDev: |
|
|
|
Financers (Hist.): Lumiplan, Vizille Capital Innovation (CIC group), Pays de Loire Développement, Sodera |
|
|
|
Note: no legal accounting report since 2007 |
MABlife |
2000 |
IDF |
Discovery, Drugs |
Personal venture | |
Cancers |
Clinical |
|
Évry |
Key words: MABs, Antibody-based therapeutics, Cancer, Immuno-therapy, Angiogenesis |
Managing Dir.-CEO: Vallet (François) [born 1958, Polytechnique, Ph.D. physics, ex-Genewave (co-founder)] |
|
(near Paris) |
Mission: to develop proprietary antibody-based therapeutics for the treatment of cancer |
Sc.Dir.-CSO: Boumsell (Laurence) |
|
|
Clients: Pharmaceutical industry (own development up to phase II included) |
Fin.Dir.-CFO: vacant |
http://www.mablife.com |
|
Age: 20 year(s) |
BusDev: vacant |
|
|
|
Financers (Hist.): Génopole 1er Jour, IxCore, Anvar |
|
|
|
Notes : full company legal name is Monoclonal Antibodies Therapeutics, up to 2011 ; previous URL was www.matbiopharma.fr ; |
Magnisense |
2003 |
IDF |
Discovery, Diagnostics |
Start-up | |
Point of Care Testing |
Trade |
|
Rosny-sous-Bois (near Paris) |
Key words: Magnetic immunoassays, In-vitro diagnostics, Point-of-Care, Rapid tests, Super-paramagnetic particles, Magnetic detection, Portable reader, Cardiac markers, Infections, MIAtek, MIAstrip, MIAflo |
Managing Dir.-CEO: Lenglet (Luc) [born 1964, Ph.D., Normale Sup (Paris), ex-Rhodia, Arthur D. Little] |
|
|
Mission: to develop and market next-generation magnetic immunoassays that improve rapid diagnostic performance for human and animal diagnostics, food safety and environmental protection testing (immunoassays that are based on magnetic bead markers, which can be used to achieve the accuracy of laboratory testing with the ease of use of rapid test methods) |
Sc.Dir.-CSO: Nikitin (Petr) [Ph.D.] |
|
|
Clients: Diagnostic industry |
Fin.Dir.-CFO: |
www.magnisense.com |
|
Age: 17 year(s) |
RegMktg: El Yousfi (Hayat) [Mme, Pharm.D.] |
|
|
|
BusDev: Péquignot (Clayton) [Ms. Biotechnology, ex-Cap Gemini Ernst and Young, Venstrata] |
|
|
|
Financers (Hist.): Baring Vostok Capital Partners, Psilos Group, Seventure, Creadev (registered capital 2007 = 0.1 M€) |
|
|
|
Note : legal foundation, February 20. 2007 (not 2003, as per company) |
Mapreg |
2000 |
IDF |
Discovery, Drugs |
Academic | |
CNS |
Clinical |
|
Le Kremlin-Bicêtre |
Key words: Microtubules, CNS diseases, Spinal cord injury, Traumatic brain injury, Neurosteroids |
Managing Dir.-CEO: Baulieu (Etienne Emile) [born 1926, M.D., Ph.D.] |
|
(near Paris) |
Mission: to dscover new drugs based on a novel mechanism for the protection and repair of nerve connections |
Managing Dir.-CEO (co-): Villey (Isabelle) [Ph.D., MBA, ex-Vision Institute] |
|
|
Clients: Pharmaceutical industry (own development up to phase II included) |
Sc.Dir.-CSO: Robel (Paul) [M.D.] |
www.mapreg.com |
|
Age: 20 year(s) |
Oper.Dir.-COO: Baeuerle (Ralf) [PhD] |
|
|
|
Fin.Dir.-CFO: |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): |
|
|
|
Note: according to the company (November 2012, but website not regularly updated), total raised capital is close to 5 M€. |
Mauna Kea Technologies |
2000 |
IDF |
Discovery, Diagnostics |
Personal venture | |
Multiple |
Trade |
|
Paris |
Key words: Fluorescence, Fiber optic, Microscopy, Pneumology, Gastrology, CellVizio |
Managing Dir.-CEO: Loiseau (Sacha Alexandre) [co-founder, born 1970, Ph.D., Eng. École Polytechnique, ex-CNES] |
|
|
Mission: to develop in vivo cellular imaging systems for biomedical and medical applications |
Sc.Dir.-CSO: Lacombe (François) [Ph.D. astrophysics, Normale Sup] |
|
|
Clients: Specialist doctors |
Fin.Dir.-CFO: Cohen (Éric) [MBA, ex-Biocortech, Hybrigenics, Teva, Radio BFM] |
www.maunakeatech.com |
|
Age: 20 year(s) |
BusDev: |
|
|
|
Financers (Hist.): Psilos Group, Seventure, CreAdev |
Medesis Pharma |
2003 |
Langeudoc-Roussillon |
Discovery, Drugs |
Personal venture | |
Multiple |
Clinical |
|
Baillargues |
Key words: Nanotechnology drug delivery systems, Metals low doses, Vanadium, Manganese, Strontium, Metabolic syndrome, Diabetes, Huntington Disease, Bipolar Disorders |
Managing Dir.-CEO: Maurel (Jean-Claude) [founder, born 1946, M.D., M.Sc., ex-Natura Medica (founder)] |
|
(near Montpellier) |
Mission: to develop new innovative treatments of diabetes and neurodegenerative disorders based on metallic ions technology and delivery of nucleic acid (siRNA antisens) |
Sc.Dir.-CSO: Maurel (Patrick) [Ph.D., ex-Inserm] |
|
|
Clients: undisclosed |
Oper.Dir.-COO: Jackson (Peter) [Ph.D.] |
www.medesispharma.com |
|
Age: 17 year(s) |
Fin.Dir.-CFO: |
|
|
|
BusDev: Jackson (Peter) |
|
|
|
Financers (Hist.): privately owned |
Mellitech |
2005 |
Rhône-Alpes |
Discovery, Drugs |
Spin-off | |
Cardiovasc |
Preclin |
|
Grenoble |
(also, Design, Diagnostics) |
Managing Dir.-CEO: Platford (Richard) [Ms. mechanical sciences (Cambridge), MBA (LBS), ex-PricewaterhouseCoopers, Cellvir] |
|
|
Key words: Type 2 diabetes, Zinc transporter protein |
Sc.Dir.-CSO: Chimienti (Fabrice) [Ph.D.] |
|
|
Mission: to develop a new therapeutic and diagnostic approach to type II diabetes based on a proprietary (PCT) zinc transporter protein, only present in insulin-secreting cells |
Oper.Dir.-COO: Girod-Roux (Pierre-Marie) [also board chairman, DEA (Physiology), Ms. management] |
www.mellitech.com |
|
Clients: undisclosed |
Fin.Dir.-CFO: |
|
|
Age: 15 year(s) |
BusDev: de Boysson (Yann) [co-founder, Engineer] |
|
|
|
Financers (Hist.): privately owned (registered capital 2006 = 0.08 M€) |
Metabolys |
2008 |
Rhône-Alpes |
Contract, Research |
Spin-off | |
Testing |
Proof-of-Concept |
|
Lyon |
Key words: Metabolomics, Toxicity, Drug candidate |
Managing Dir.-CEO: Baverel (Gabriel) [born 1947, founder, M.D., University Prof. Lyon] |
|
|
Mission: to improve the preclinical evaluation of drug candidates through cellular metabolomics in pharmacology, toxicology and nutrition (identification and quantification of metabolic pathways by the combination of enzymatic and carbon 13 NMR measurements with mathematical models of metabolic pathways) |
Sc.Dir.-CSO: Baverel (Gabriel) |
|
|
Clients: Pharmaceutical industry, Research labs |
Fin.Dir.-CFO: |
www.metabolys.org |
|
Age: 12 year(s) |
BusDev: |
|
|
|
Financers (Hist.): privately owned (registered capital 2008 = 0.15 M€) |
|
|
|
Note: web site, still under construction since inception (May 2011) |
MilleGen |
1999 |
Midi-Pyrénées |
Contract, Manufacturing |
Personal venture | |
Multiple |
Subcontractor |
|
Labège |
(also, Development, Drugs) |
Managing Dir.-CEO: Kharrat (Abdel Hakim) [co-founder, born 1961, Ph.D. biology, Ms. Management, ex-EMBL Heidelberg] |
|
(near Toulouse) |
Key words: Directed Molecular Evolution (DME), MutaGen, Mutascreen, Gene cloning, High throughput screening, Antibodies, Peptides |
Sc.Dir.-CSO: Bouayadi (Khalil) [co-founder, Ph.D. molecular pharmacology] |
|
|
Mission: to develop and and genetically engineer new human therapeutic antibodies based on proprietary Directed Molecular Evolution platform, for third parties and for own pipeline (also, to offer custom services including high-throughput DNA sequencing, bioinformatics, gene cloning and vector development services, peptides synthesis and antibodies engineering and production) |
I.T.Dir.-CIO: Crozet (Fabien) [Ph.D. molecular neurobiology] |
www.millegen.com |
|
Clients: Pharmaceutical industry, Research labs, Biotechs |
Fin.Dir.-CFO: |
|
|
Age: 21 year(s) |
BusDev: Deflisque (Anne) [Ms. biochemistry, ex-GE Healthcare] |
|
|
|
Financers (Hist.): privately owned (registered capital 2006 = 0.07 M€) |
Murigenetics |
2005 |
Méditerranée |
Discovery, Drugs |
Personal venture | |
Genome |
Preclin |
|
Marseille |
Key words: Genetic diseases, Charcot-Marie-Tooth (CMT), Hereditary neuropathy, Genetic mental disorders |
Managing Dir.-CEO: Berro (Marine) [born 1980, ESIL] |
|
|
Mission: to develop new drugs for the treatment of serious genetic diseases, based on internal production of genetically modified animal models expressing human genes of patients with hereditary peripheral neuropathies, or mental retardation |
Sc.Dir.-CSO: |
|
|
Clients: Prescribers |
Fin.Dir.-CFO: |
www.murigenetics.com |
|
Age: 15 year(s) |
BusDev: |
|
|
|
Financers (Hist.): grants by Association Française pour le traitement de la Myopathie (AFM, i.e. French Muscular Dystrophy Association), privately owned (registered capital 2006 = 0.04 M€) |
|
|
|
Note : on legal accounts, company have only 1 headcount in 2010 ; at the end of 2011, legal accounts mention 2 headcounts, no revenues and major deficits ; in November 2012, the company website is inactive and the URL dropped |
NanoBiotix |
2003 |
IDF |
Design, Drugs |
Personal venture | |
Cancers |
Clinical |
|
Paris |
Key words: Nanoparticles, Cancer, NanoXray, Nbtxr3 |
Managing Dir.-CEO: Levy (Laurent) [co-founder, born 1971, Ph.D. physical chemistry, ex-Altran] |
|
|
Mission: to develop new cancer treatments based on proprietary NanoXray platform, as an injection of patented X-ray activated nanoparticles |
Sc.Dir.-CSO: |
|
|
Clients: Hospitals |
Oper.Dir.-COO: Boussaha (Kader) [co-founder, born 1973, Eng. ENI, ex-Altran] |
www.nanobiotix.com |
|
Age: 17 year(s) |
Med.Dir.: Borghi (Elsa) [M.D., ex-Sanofi-Aventis] |
|
|
|
Fin.Dir.-CFO: |
|
|
|
BusDev: Mühlenweg (Bernd) [Ph.D. chemistry, Munich, ex-Wilex] |
|
|
|
Financers (Hist.): Cap Décisif, Amorçage Rhône Alpes, Matignon Technologies, OTC Asset Management |
|
|
|
Note: an IPO is being prepared in Fall 2012 |
Neorphys |
2005 |
Méditerranée |
Discovery, Drugs |
Personal venture | |
Multiple |
Preclin |
|
Nîmes |
Key words: Nausea-free acute pain, Morphine derivatives, Opioids, Analgesics |
Managing Dir.-CEO: Lahana (Roger) [co-founder, born 1954, ex-Syntem] |
|
|
Mission: to develop a new family of opioid analgesic drug candidates with low side effects |
Sc.Dir.-CSO: |
|
|
Clients: Pharmaceutical industry (own development up to phase IIb) |
Oper.Dir.-COO: Larbouret (Karine) [co-founder, ex-Syntem] |
www.neorphys.com |
|
Age: 15 year(s) |
Fin.Dir.-CFO: |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): Soridec, Inserm-Transfert, CEA Valorisation, Fa Diese 2, Seillans, plus independent business angels |
Neovacs |
1993 |
IDF |
Discovery, Immunology |
Spin-off | |
Cancers |
Clinical |
|
Paris |
Key words: Therapeutic vaccines, Cancer, Inflammatory diseases, Antibodies, Kinoids, Toxoids |
Managing Dir.-CEO: Fanneau de la Horie (Guy-Charles) [born 1959, Vet.D., MBA, ex-IDM, Biogen (President Europe), Schering-Plough] |
|
|
Mission: to develop anti-cytokine and anti-protein viral regulation therapeutic vaccines to treat certain cancers and inflammatory diseases |
Sc.Dir.-CSO: Grouard-Vogel (Géraldine) [Pharm.D., Ph.D. immunology, ex-Aventis Pasteur, Walter Reed Army Institute] |
|
|
Clients: Prescribers |
Pharm.Dir.: Fanget (Bernard) [ex-Flamel, Sanofi Pasteur] |
www.neovacs.com |
|
Age: 27 year(s) |
Fin.Dir.-CFO: |
|
|
|
BusDev: Whitehead (Piers) [Oxford, ex-VaxGen, Mercer Management Consulting] |
|
|
|
Comm.Dir.: Hocdée-Leroy (Florence) [EM Lyon, ex-Rhône-Poulenc, KBC Securities, Grosvenor] |
|
|
|
Financers (Hist.): Truffle Ventures, Europe Innovation, Debiopharm, Novartis, OTC Asset Management |
|
|
|
note : at the end of December 2010, Novartis shares account for 26.6% |
Netris-Pharma |
2008 |
Rhône-Alpes |
Discovery, Drugs |
Personal venture | |
Cancers |
Proof-of-Concept |
|
Lyon |
Key words: Breast cancer, Metastasis, Dependence receptors, Targeted Therapy |
Managing Dir.-CEO: Bernet (Agnès) [co-founder, born 1968, CNRS] |
|
|
Mission: to develop therapeutic compounds for the treatment of cancer, in particular of breast cancer and NSC Lung cancer |
Sc.Dir.-CSO: Bernet (Agnès) |
|
|
Clients: undisclosed |
Fin.Dir.-CFO: |
www.no-website.net |
|
Age: 12 year(s) |
BusDev: |
|
|
|
Financers (Hist.): privately owned (registered capital 2009 = 0.04 M€) |
Neuronax |
2003 |
Centre |
Discovery, Drugs |
Spin-off | |
CNS |
Proof-of-Concept |
|
Saint Beauzire |
(also Contract, Services) |
Managing Dir.-CEO: Gobron (Stéphane) [born 1968] |
|
(near Clermont-Ferrand) |
Key words: Neural repair, Parkinson disease, Ataxy, NX peptides |
Sc.Dir.-CSO: Gobron (Stéphane) |
|
|
Mission: to develop new drugs for neural repair in cases of neuro-traumas and neuro-degenerative disorders |
Fin.Dir.-CFO: |
www.neuronax.com |
|
Clients: Pharmaceutical industry (out-licensing after proof-of-concept) |
BusDev: |
|
|
Age: 17 year(s) |
Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€) |
NewVectys |
2010 |
IDF |
Contract, Research |
Personal venture | |
Multiple |
Preclin |
|
Paris |
Key words: Gene-Transfer, Vectorology, Translational-Research, Gene-Therapy, Transgenic-Models |
Managing Dir.-CEO: Duboscq (Antoine) [co-founder, born 1968, ex-Procter & Gamble, Boston Consulting Group, WMI] |
|
|
Mission: to develop innovative gene transfer technologies and their applications in transgenic large animal models and gene therapy (own research and co-development as subcontractor) |
Sc.Dir.-CSO: Sarkis (Chamsy) [co-founder, born 1974, Ph.D., ex-CNRS] |
|
|
Clients: Pharmaceutical industry, Medical devices industry, Biotechs and CROs |
Fin.Dir.-CFO: |
www.newvectys.com |
|
Age: 10 year(s) |
BusDev: |
|
|
|
Financers (Hist.): privately owned (registered capital 2011 = 0.25 M€) |
NicOx |
1996 |
Méditerranée |
Delivery, Drugs |
Start-up | |
Multiple |
Pre-reg |
|
Nice |
Key words: Nitric oxide, Inflammation, Cardio-metabolic, Osteo-arthritis |
Managing Dir.-CEO: Garufi (Michele) [co-founder, born 1954, Pharm.D., ex-Recordati, Italfarmaco] |
|
|
Mission: to develop and market investigational nitric oxide-donating drugs to meet unmet medical needs, based on proprietary nitric oxide-donating technology |
Sc.Dir.-CSO: Pfister (Pascal) [M.D., Pharm.D., ex-Novartis, Sandoz] |
|
|
Clients: Prescribers |
Fin.Dir.-CFO: Castaldi (Eric) |
www.nicox.com |
|
Age: 24 year(s) |
BusDev: Spencer (Gavin) [Ph.D. chemistry, ex-Novartis, Boots] |
|
|
|
Financers (Hist.): Apax Partners, Sofinnova, European Medical Ventures, Paribas P.I., Health Capital AB, Oppenheimer Funds, QVT Fund, AQR Capital Management, Pfizer Overseas, Baker Brothers Investments, Public, Managers (less than 3% in 2008) |
Nokad |
2004 |
IDF |
Discovery, Targets |
Personal venture | |
Studies |
Trade |
|
Évry |
Key words: Secreted proteins inactivation, Functional knock-out, Protein vaccination, Mammals |
Managing Dir.-CEO: Abina (Amine, Mohammed) [co-founder, born 1963, M.D. immunology, Ph.D., ex-AFSSAPS] |
|
(near Paris) |
Mission: to develop and market functional inactivation (knock-out) of secreted endogenous proteins in mammals, through direct in vivo induction of a specific immune response against an endogenous target |
Sc.Dir.-CSO: Erard (François) [Ph.D., University Professor, ex-Novartis] |
|
|
Clients: Pharmaceutical industry, Research labs |
Fin.Dir.-CFO: |
www.nokad-technology.com |
|
Age: 17 year(s) |
BusDev: |
|
|
|
Financers (Hist.): Cap Décisif and Genopole 1er Jour, SHAM (Société Hospitalière d’Assurances Mutuelles), privately owned |
Nosopharm |
2009 |
Méditerranée |
Discovery, Drugs |
Personal venture | |
Infections |
Proof-of-Concept |
|
Nîmes |
Key words: Anti-infectives, Clostridium difficile, Multi-resistant Gram-negative pathogens |
Managing Dir.-CEO: Villain-Guillot (Philippe) [co-founder, born 1977] |
|
|
Mission: to discover and develop novel antibiotics against nosocomial and emerging infections |
Sc.Dir.-CSO: Gualtieri (Maxime) [co-founder, ex-CNRS] |
|
|
Clients: Biotechs, Pharmaceutical industry (own development up to phase I) |
Fin.Dir.-CFO: |
www.nosopharm.com |
|
Age: 11 year(s) |
BusDev: |
|
|
|
Financers (Hist.): privately owned (registered capital 2009 = 0.02 M€) |
NovAliX |
2002 |
Alsace |
Discovery, Drugs |
Spin-off | |
Multiple |
Preclin |
|
Strasbourg-Illkirch |
(also Design, Protein) |
Managing Dir.-CEO: Zeyer (Denis) [born 1972, Ph.D., ex-IGBMC] |
|
|
Key words: NHR (Nuclear Hormone Receptors), Ligands, Protein crystallography, Cancer, Type II diabetes, Obesity, Early-stage |
Sc.Dir.-CSO: Zeyer (Denis) |
|
|
Mission: to discover, from early-stage, drugs based structure-based design using X-ray crystallography, with a main interest in nuclear hormone receptors, for cancers, type II diabetes, obesity and other metabolic diseases, also for neglected diseases such as schistosomiases, and to provide third parties with service activities in protein crystallization protein crystallography, and ligand screening using mass spectrometry |
Fin.Dir.-CFO: |
www.alix-pharma.com |
|
Clients: Research labs |
BusDev: |
|
|
Age: 18 year(s) |
Financers (Hist.): privately owned (registered capital 2006 = 0.07 M€) |
|
|
|
Note: Alix has become, end of 2008, a subsidiary of Novalix, then Alix has been discontinued in 2009 ; no legal reports since 2006 for Novalix (and also Alix) ; Jenn (Stephan) [born 1968] is president of the company |
NovoCIB |
2005 |
Rhône-Alpes |
Contract, Research |
Personal venture | |
Virus |
Subcontractor |
|
Lyon |
(also, Discovery, Drugs) |
Managing Dir.-CEO: Godard (Nicolas) [Ms. microbiology (INA), MBA] |
|
|
Key words: Nucleotides, Antivirals, HCV, Enzymes, Precice platform |
Sc.Dir.-CSO: Balakireva (Larissa) [founder, born 1966, Ph.D. Cell Biology, ex-IBS], also President |
|
|
Mission: to provide third parties with a wide range of products and services, as nucleoside kinase phosphorylation assays, IMPDH or PNP inhibition assays, nucleotides and nucleosides bio-analysis, in cell extract or body fluids (including clinical samples) or the evaluation of the metabolic impact of compounds intended for therapeutic applications in oncology and virology or as immunosuppressive agents, and to develop own anti-viral nucleoside analogues |
Fin.Dir.-CFO: |
www.novocib.com |
|
Clients: Pharmaceutical Industry, Biotechs |
BusDev: |
|
|
Age: 15 year(s) |
Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€) |
Novotec |
1997 |
Rhône-Alpes |
Contract, Manufacturing |
Spin-off | |
Multiple |
Subcontractor |
|
Lyon |
Key words: Antibodies, Extra cellular matrix (ECM), Tissue-samples, Immunochemistry, Histology |
Managing Dir.-CEO: Guerret (Sylviane) [born 1950] et Hartmann (Danielle) [born 1953] |
|
|
Mission: to develop, produce and distribute species specific antibodies directed against macro-molecules of the Extracellular Matrix (ECM), to prepare tissue analysis |
Sc.Dir.-CSO: Hartmann (Daniel) |
|
|
Clients: Pharmaceutical industry, Cosmetic industry, Biotechs, Academic and Industry Research labs |
Fin.Dir.-CFO: |
www.novotec-labs.com |
|
Age: 23 year(s) |
BusDev: Prulière (Franck) |
|
|
|
Financers (Hist.): privately owned (registered capital 2006 = 0.065 M€) |
|
|
|
Note: no communication policy on web site |
Obe Therapy |
2000 |
IDF |
Discovery, Targets |
Personal venture | |
Cardiovasc |
Preclin |
|
Évry |
(also, Discovery,, Drugs) |
Managing Dir.-CEO: |
|
(near Paris) |
Key words: Gene targets, Intestine, Obesity, Hyper-cholesterolemia, Type II diabetes |
Sc.Dir.-CSO: Harosh (Itzik Isaac) [founder, born 1954, Ph.D., ex-GlaxoWelcome, CNRS, Technion (Israel)] and Braud (Sandrine) [also COO, Ph.D., ex-CEA, Institut Pasteur] |
|
|
Mission: to discover new targets and to develop new drugs for obesity, hypercholesterolemia and type II diabetes, based on the identification of gene targets associated with a lean phenotype |
Fin.Dir.-CFO: |
www.obetherapy.com |
|
Clients: Pharmaceutical industry |
BusDev: |
|
|
Age: 21 year(s) |
Financers (Hist.): privately owned (registered capital 2006 = 0.06 M€) |
|
|
|
Note: no communication policy on web site |
Oligovax |
2000 |
IDF |
Discovery, Immunology |
Start-up | |
Cancers |
Clinical |
|
Paris |
Key words: Oligo-nucleotides, Immuno-stimulants, Cancer, Liténimod |
Managing Dir.-CEO: van der Schueren (Paul) [founder, born 1963, MBA] |
|
|
Mission: to develop innovative anti-cancer therapies belonging to a new therapeutic class, TLR9 agonists |
Sc.Dir.-CSO: Richard (Margaretha) [Pharm.D., ex-Pierre Fabre, AP-HP] |
|
|
Clients: Prescribers |
Fin.Dir.-CFO: |
www.oligovax.com |
|
Age: 20 year(s) |
BusDev: |
|
|
|
Financers (Hist.): Global Millenium Fund |
|
|
|
Communication: no website news update since 2006, no legal information available since end 2005 |
|
|
|
Note : webhosting with Lycos withdrawn in March 2009 |
Oncodesign |
1995 |
Rhône-Alpes |
Contract, Research |
Personal venture | |
Studies |
Subcontractor |
|
Dijon |
(also, Discovery, Therapies) |
Managing Dir.-CEO: Genne (Philippe) [co-founder, born 1961, Ph.D.] |
|
|
Key words: In-vivo screening, Nude-rat, Cancer, Drug resistance, Translational research, Neurology |
Sc.Dir.-CSO: |
|
|
Mission: to provide third parties with preclinical evaluation of novel anticancer therapeutics and to identify and validate molecular targets involved in cancer pathologies |
Fin.Dir.-CFO: |
www.oncodesign.fr |
|
Clients: Pharmaceutical industry |
BusDev: Ewing (Jonathan) |
|
|
Age: 25 year(s) |
Financers (Hist.): CDC, Avenir Entreprise Gestion, Banque de Vizille |
OriBase Pharma |
2007 |
Méditerranée |
Contract, Research |
Personal venture | |
Studies |
Subcontractor |
|
Montpellier |
Key words: Computational chemistry, Predictive-interpretative model building, QSAR/QSPR datamining, Structure-Activity relationships, SARA platform |
Managing Dir.-CEO: Yasri (Aziz) [co-founder, born 1966, Ph.D. biophysics and drug sciences, ex-Syntem, ArQule, J&J, Nova Decision] |
|
|
Mission: to provide third parties with medicinal chemistry oriented tools and services (chemo-informatics, molecular modelling and bio-informatics) from Hit Identification to Lead Optimisation |
Sc.Dir.-CSO: Yasri (Aziz) |
|
|
Clients: Pharma industry, Agro industry, and Biotechs |
Chem.Dir.: Cazals (Bénédicte) [Ph.D. organic chemistry, ex-Idenix, Azasynth] |
www.oribase-pharma.com |
|
Age: 13 year(s) |
I.T.Dir.: Chevé (Gwénaël) [Ph.D. medicinal chemistry, ex-Pierre Fabre] |
|
|
|
Fin.Dir.-CFO: |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): privately owned |
|
|
|
Notes : in December 2010, the initial websites of the forming companies are still active under www.novadecision.com and www.azasynth.com ; foundation date of Oribase Pharma selected as that of Azasynth, i.e. only 1 month before Nova Decision |
Oroxcell |
2004 |
IDF |
Contract, Services (also, Delivery, Drug) |
Personal venture | |
Studies |
Subcontractor |
|
Romainville |
Key words: Skin models (human), Pre-clinical testing, Drug delivery pre-formulation, Innovative formulations, Oral bioavailability |
Managing Dir.-CEO: Pachot (Jean) [founder, born 1960, Eng. biochemistry, ex-Roussel Uclaf, Aventis] |
|
(near Paris) |
Mission: to conduct preclinical studies (in vitro ADME, Animal PK on rodents, Phys-Chem testing, Bioanalysis) for third parties, plus to develop own research in cell culture and innovative formulations, financed by CRO cash-flow |
Sc.Dir.-CSO: Pachot (Jean) |
|
|
Clients: Pharmaceutical industry, Research labs, Cosmetic industry, Food industry, Veterinary industry |
Chem.Dir.-CTO: Dini (Christophe) [born 1962, ex-Roussel Uclaf, Aventis] |
www.oroxcell.com |
|
Age: 16 year(s) |
Fin.Dir.-CFO: |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): privately owned (registered capital 2007 = 0.3 M€) |
Oxincell |
2006 |
Méditerranée |
Contract, Services |
Personal venture | |
Virus |
Preclin |
|
Montpellier |
Key words: Mitochondria, Oxymetry measurement, Toxicology, Antivirals |
Managing Dir.-CEO: Peyreigne (Christelle) [co-founder, born 1969, Ph.D. physiology, Inserm] |
|
|
Mission: to provide third parties with optimized oximetric analysis of mitochondrial activity |
Sc.Dir.-CSO: |
|
|
Clients: Pharmaceutical industry, Biotechs, Research labs |
Fin.Dir.-CFO: |
www.oxincell.com |
|
Age: 14 year(s) |
BusDev: |
|
|
|
Financers (Hist.): privately owned |
|
|
|
Communication: no website news update since 2006 in February 2010 |
Palumed |
2000 |
Midi-Pyrénées |
Discovery, Drugs |
Personal venture | |
Infections |
Preclin |
|
Toulouse |
Key words: Anti-malarial, Antibacterial, Covalent bi-therapy, Trioxaquines |
Managing Dir.-CEO: Meunier (Bernard) [born 1947, ex-Polytechnique (Professor), CNRS (President)] |
|
|
Mission: to develop new antimalarial agents and also new antibacterial molecules and chelating agents for the treatment of neurodegenerative diseases |
Sc.Dir.-CSO: |
|
|
Clients: Pharmaceutical industry (Sanofi-Aventis) |
Fin.Dir.-CFO: |
www.palumed.com |
|
Age: 20 year(s) |
BusDev: Meunier-Chesny (Claudine) [born 1949] |
|
|
|
Financers (Hist.): IRDI, SOCRI, FCJE (CDC), GSO Capital, Viveris |
PharmaLeads |
2000 |
IDF |
Design, Drugs |
Personal venture | |
Multiple |
Trade |
|
Paris |
(also, Discovery, Drugs) |
Managing Dir.-CEO: Bourbié (Thierry) [born 1952, Polytechnique-Mines, Ph.D. Geophysics, ex-Suez, Schlumberger] |
|
|
Key words: Enzymes, Zinc Metallopeptidases, Substrates, Inhibitors, Fluofast, Analgesia |
Sc.Dir.-CSO: Roques (Bernard Pierre) [Ph.D., ex-Inserm, Polytechnique (Assistant Prof.)] |
|
|
Mission: to develop custom design of substrates and inhibitors of all types of proteases for three main applications, on-demand design of optimised substrates and/or inhibitors for pharmaceutical companies, internal drug discovery in the field of analgesia, leading services in botulinum toxin detection and assay |
Fin.Dir.-CFO: Maillard (Pierre) [MBA-ESSEC, ex-Dassault Aviation, Suez Environment] |
www.pharmaleads.com |
|
Clients: Research labs, Pharmaceutical industry |
BusDev: Wurm (Michel) [M.D.] |
|
|
Age: 20 year(s) |
Financers (Hist.): undisclosed |
Pharnext |
2007 |
IDF |
Delivery, Drugs |
Start-up | |
Orphan |
Clinical |
|
Paris |
Key words: Drug Repositioning, Charcot Marie Tooth disease, Orphan drugs, Pleotherapy |
Managing Dir.-CEO: Cohen (Daniel) [co-founder, born 1951, Ph.D., ex-Genset, Millenium] |
|
|
Mission: to develop innovative treatments for serious neurological diseases, notably peripheral neuropathies (Charcot Marie Tooth, peripheral diabetic neuropathy), and possibly Alzheimer, by implementing a drug repositioning approach which aims to expand the indications for existing medicines |
Sc.Dir.-CSO: Chumakov (Ilya) [Ph.D. chemistry, D.Sc. Molecular Biology, ex-CEPH, Genset, Serono Genetics Institute |
|
|
Clients: Prescribers |
Fin.Dir.-CFO: Heidsieck (Loïc) [ex-Arthur Young, Autologic, Franklin Mint, Serono, Genset] |
www.pharnext.com |
|
Age: 13 year(s) |
BusDev: |
|
|
|
Financers (Hist.): Truffle Capital, Aurinvest, Financière Boscary, Parinvest (Jean-Charles Naouri), Financière Gaspard |
PhenoPro |
2007 |
Alsace |
Contract, Services |
Spin-off | |
Studies |
Trade |
|
Illkirch |
(also, Contract, Research) |
Managing Dir.-CEO: Schaeffer (Catherine) [born 1962] |
|
(near Strasbourg) |
Key words: Translational medicine, Mouse phenotyping, Targets |
Sc.Dir.-CSO: |
|
|
Mission: to provide third parties with advanced mouse phenotyping-based translational medicine tools and expertise, in order to improve biopharmaceutical drug R&D productivity and patient access to safer and more efficacious drugs |
Fin.Dir.-CFO: |
www.phenopro.com |
|
Clients: Research labs |
BusDev: Bocquel (François) [M.D., I.A.E., ex-Erudia, UCB Pharma, Parke Davis, Pfizer |
|
|
Age: 13 year(s) |
Financers (Hist.): privately owned |
|
|
|
Communication: no legal accounting information available since inception |
Pherecydes Pharma |
2006 |
IDF |
Discovery, Drugs |
Spin-off | |
Infections |
Preclin |
|
Romainville |
Key words: Antibacterials, Phage genes, Emerging problems, Defense, Bio-threat, Libraries of bacteriophages |
Managing Dir.-CEO: Gabard (Jérôme) [born 1961, Ph.D., ex-Marketech, DuPont de Nemours] |
|
(near Paris) |
Mission: to develop, then to introduce new products against multi-resistance bacteria, combining surveillance, detection and therapeutic tools based on phage technology, as a bio-defense and bio-security company |
Sc.Dir.-CSO: Iris (François) [co-founder] |
|
|
Clients: undisclosed |
R&D Dir.-CTO: Pouillot (Flavie) [Ph.D. Microbiology, ex-Institut Pasteur] |
www.pherecydes-pharma.com |
|
Age: 14 year(s) |
BusDev: |
|
|
|
Financers (Hist.): Biosecurity, Financière de Brienne |
PolyIntell |
2004 |
IDF-Normandy |
Contract, Research |
Personal venture | |
Studies |
Subcontractor |
|
Val-de-Reuil (south Rouen) |
(also, Contract, Manufacture) |
Managing Dir.-CEO: Naraghi (Kaynoush) [co-founder, born 1970, Ph.D., Ms. management] |
|
|
Key words: Molecularly Imprinted Polymers, MIP, AFFINIMIP, Intelligent polymers, Selectivity, Solid phase extraction, Purification, Miniaturisation, Hydrogel, Sample preparation, Diagnostics |
Sc.Dir.-CSO: Bayoudh (Sami) [co-founder, Ph.D.] |
|
|
Mission: to develop, manufacture and market more accurate analytical and diagnostic tools for pharmaceutical R&D and food safety, plus to operate own research in new polymers, financed by CRO cash-flow |
Oper.Dir.-COO: Arotçarena (Michel) [Ph.D.] |
www.polyintell.com |
|
Clients: Pharmaceutical industry, Chemical industry, Food industry |
Fin.Dir.-CFO: |
|
|
Age: 16 year(s) |
BusDev: |
|
|
|
Financers (Hist.): privately owned |
Proteogenix |
2003 |
Alsace |
Discovery, Diagnostics |
Personal venture | |
Cancers |
Trade |
|
Oberhausbergen |
(also Contract, Services) |
Managing Dir.-CEO: Funfrock (Philippe) [co-founder, born 1978] |
|
(near Strasbourg) |
Key words: Custom Antibodies, Recombinant proteins, Peptide synthesis, Gene synthesis, Cancer screening, Biomarkers |
Sc.Dir.-CSO: Hopfner (Raphaël) |
|
|
Mission: to discover new diagnostic markers in cancer through targeted screenings and to provide third parties with polyclonal and monoclonal antibody development, recombinant protein production and purification, gene synthesis and peptide synthesis |
Fin.Dir.-CFO: |
www.proteogenix-antibody.com |
|
Clients: Research labs |
BusDev: |
|
|
Age: 18 year(s) |
Financers (Hist.): Oséo, privately owned |
|
|
|
Note : Proteogenix will move in brand new state of the art facilities by 2011 |
Protexel |
2000 |
IDF |
Discovery, Drugs |
Spin-off | |
Liver |
Clinical |
|
Paris |
Key words: Immunology, Alcoholic hepatitis, Liver cancer, Cirrhosis, Chemical mimetics, Anti-oxydant, Superoxyde dismutase, Mangafodipir |
Managing Dir.-CEO: Batteux (Frédéric) [Batteux (Arman), born 1939, legally as President] |
|
|
Mission: to develop innovative treatments for severe liver conditions |
Sc.Dir.-CSO: |
|
|
Clients: Pharmaceutical industry (own development up to phase III) |
Fin.Dir.-CFO: |
www.no-website.net |
|
Age: 20 year(s) |
BusDev: |
|
|
|
Financers (Hist.): |
|
|
|
Note : no Company website since inception |
PX’Therapeutics |
2000 |
Rhône-Alpes |
Contract; Research |
Personal venture | |
Multiple |
Trade |
|
Grenoble |
(also, Contract, Manufacturing) |
Managing Dir.-CEO: Rousselle (Tristan) [co-founder, born 1970, Ph.D. cellular biology] |
|
|
Key words: Recombinant protein engineering |
Sc.Dir.-CSO: Mouz (Nicolas) [co-founder, born 1966, Ph.D. molecular biology] |
|
|
Mission: to develop biotherapeutics (valuable recombinant proteins) from early stage research up to cGMP production through its specialized technology and manufacturing platforms Protein’eXpert, PX’Monoclonals and PX’Pharma, for third parties |
Prod.Dir.-CTO: Mouz (Sebastien) [Ph.D.] |
www.px-therapeutics.com |
|
Clients: Pharmaceutical industry, Biotechs |
Fin.Dir.-CFO: |
|
|
Age: 20 year(s) |
BusDev: Untereiner (Claire) |
|
|
|
Financers (Hist.): Vizille Capita (and others), privately owned (registered capital 2007= 0.13 M€) |
Quantum Genomics |
2006 |
IDF |
Discovery, Drugs |
Start-up | |
Multiple |
Preclin |
|
Massy |
Key words: Academic, Development platform, Co-partnering R&D |
Managing Dir.-CEO: Segard (Lionel) [born 1968, Biochemistry, ex-Inserm-Transfert (CEO), IBM, TFSM] |
|
(near Paris / HQ |
Mission: to maximize the developments and discoveries of academic research into breakthrough treatments for human disease, in cardiovascular diseases, neurology and metabolic related diseases |
Sc.Dir.-CSO: Riffaud (Jean-Pierre) [Pharm.D., ex-Cellpep, NicOx, Fournier, Debat] |
|
Jersey City |
Clients: Pharmaceutical industry |
Fin.Dir.-CFO: |
www.quantum-genomics.com |
USA) |
Age: 15 year(s) |
BusDev: |
|
|
|
Financers (Hist.): |
Rhenovia Pharma |
2007 |
Alsace |
Contract, Research |
Personal venture | |
CNS |
Proof-of-Concept |
|
Mulhouse |
Key words: Alzheimer, Biosimulation, Computational neuroscience, Memory |
Managing Dir.-CEO: Bischoff (Serge) [co-founder, born 1948, Ph.D. neuropharmacology, ex-Novartis] |
|
|
Mission: to contribute to discover new medicines against Alzheimer’s and other central nervous system (CNS) diseases, by developing breakthrough biosimulation platforms for memory and other CNS functions |
Sc.Dir.-CSO: Baudry (Michel) [co-founder, born 1948, Eng. Ecole Polytechnique, Prof. engineering (Los Angeles), Ph.D.] |
|
|
Clients: Pharmaceutical industry, Biotechs |
Oper.Dir.-COO: Faupel (Michel) [co-founder, ex-Novartis] |
www.rhenovia.com |
|
Age: 13 year(s) |
Fin.Dir.-CFO: |
|
|
|
BusDev: George (Florian) [Ph.D. chemistry] |
|
|
|
Financers (Hist.): privately owned, no outisde investors (registered capital 2007 = 0.126 M€) |
ScarCell Therapeutics |
2007 |
IDF |
Design, Drugs |
Spin-off | |
Cardiovasc |
Proof-of-Concept |
|
Paris |
Key words: Cell therapy project, Transplantation, Cardiovascular |
Managing Dir.-CEO: Augier (Jean-Jacques) [legally as President, born 1953] |
|
|
Mission: to carry out an autologous gingival fibroblasts transplantation in order to repair injured tissues, in particular in the field of cardiovascular pathology (vascular prosthesis for abdominal aortic aneurysm, atherosclerosis,…) and others |
Sc.Dir.-CSO: |
|
|
Clients: undisclosed |
Fin.Dir.-CFO: |
www.scarcell-therapeutics.com |
|
Age: 13 year(s) |
BusDev: |
|
|
|
Financers (Hist.): |
|
|
|
Note : URL not renewed in time (October 2009), still unavailable (February, May, October 2010, April 2011, December 2012), but legally company still active (with a new President since July 2012, Laurent Cezard, born March 1969 |
Sisène Biotechnologies |
2007 |
IDF |
Discovery, Drugs |
Academic | |
Cancers |
Preclin |
|
Paris |
Key words: Cancer, Vegf, Anti-angiogenics, Ophtalmology |
Managing Dir.-CEO: Marsac (Jean) [born 1943, co-founder, M.D., Professor] |
|
|
Mission: to discover and develop new anti-angiogenic biotherapies, in cancers and ophtalmology |
Sc.Dir.-CSO: Plouët (Jean) [deceased, co-founder, M.D., Ph.D., Professor, Inserm, ex-Abtech, Gencell, AP-HP Lariboisière] |
|
|
Clients: Pharmaceutical industry (own development up to clinical trials) |
Oper.Dir.-COO: Garreau (Martine) [born 1951, M.D., ex-Synthelabo] |
www.no-website.net |
|
Age: 13 year(s) |
Fin.Dir.-CFO: |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): ARC, ANR, InCA |
|
|
|
Note (November 2011) : the new company website is available |
Skuld-Tech |
1999 |
Méditerranée |
Design, Diagnostics |
Spin-off | |
Multiple |
Preclin |
|
Montpellier |
(also, contract, research) |
Managing Dir.-CEO: Ritter (Didier) [co-founder, born 1969, Ms. molecular biology, MBA, ex-Bio2R (founder)] |
|
|
Key words: Biomarkers, Genomics, Pharmaco-genomics, Bio-informatics, Biosensors, SAGE |
Sc.Dir.-CSO: Piquemal (David) [co-founder, Ph.D., Prof. genomics] |
|
|
Mission: to select and validate biomarkers, bioinformatics, biosensors, leading to design new diagnosis, identify new targets, and generate new leads for biopharmaceutical companies and personalized medicine |
Fin.Dir.-CFO: Outrebon (Philippe) [co-founder, Ms. sciences, ex-Ernst & Young] |
www.skuldtech.com |
|
Clients: Research labs |
BusDev: Outrebon (Philippe) |
|
|
Age: 21 year(s) |
Financers (Hist.): Oseo, Regional Territory Body, Private Investors |
Stentys |
2006 |
IDF |
Design, Devices |
Start-up | |
Cardiovasc |
Trade |
|
Paris |
Key words: Stent, Heart-Attack, Revascularisation, |
Managing Dir.-CEO: Issenmann (Gonzague) [co-founder, born 1972, MBA, ex-CordisJ&J] |
|
|
Mission: to develop a new generation of self-expanding stents or self-apposing stents, specialized in the treatment of heart attacks (or Acute Myocardial Infarction) |
Sc.Dir.-CSO: |
|
|
Clients: Device Industry, Hospitals |
Med.Dir.: Spaargaren (René) [M.D., Medtronic, Boston Scientific, EV3] |
www.stentys.com |
|
Age: 14 year(s) |
Mktg&Sales: Goffart (Lucien) [MBA, ex-J&J, Abbott , Volcano] |
|
|
|
Fin.Dir.-CFO: Piot (Stanislas) [Ms. finance and economics, ex-Ipsogen, Banque Worms, Crédit Lyonnais, Oddo, Natixis] |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): Sofinnova Partners, Scottish Equity Partners, Crédit Agricole Private Equity, FSI, Public (registered capital 2009 = 0.16 M€) |
Synapcell |
2005 |
Rhône-Alpes |
Contract, Research |
Personal venture | |
CNS |
Subcontractor |
|
Grenoble |
Key words: Preclinical development, CNS, Epilepsy, Neuronal networks |
Managing Dir.-CEO: Roucard (Corinne) [born 1969, co-founder, Ph.D., ex-Synapcell (Project Leader)] |
|
|
Mission: to provide third parties with customized solutions for preclinical evaluation of CNS therapeutics and with consulting, pre-designed and customized programs to expertise drug candidates of the biopharmaceutical industry, and also to develop own research innovative tools |
Sc.Dir.-CSO: Bressand (Karine) [born 1971, Ph.D.] |
|
|
Clients: Research labs |
Fin.Dir.-CFO: Roche (Yann) [born 1974, Ph.D. biology, Ms. Management] |
www.synapcell.com |
|
Age: 15 year(s) |
BusDev: Roche (Yann) |
|
|
|
Financers (Hist.): privately owned (registered capital 2006 = 0.09 M€) |
Synprosis |
2003 |
Méditerranée |
Discovery, Immunology |
Personal venture | |
Vaccines |
Preclin |
|
Fuveau |
(also Contract, Manufacturing) |
Managing Dir.-CEO: Salles (Jean-Pierre) [born 1954, Pharm.D., ex-Laphal (Dir. R&D)] |
|
(near Marseille) |
Key words: HIV1 vaccine, Synthetic peptides |
Sc.Dir.-CSO: |
|
|
Mission: to provide custom peptide synthesis (notably vaccines) in solid phase manufacture with high quality for basic research and for therapeutic applications (cGMP) and to develop own immunological compounds |
Fin.Dir.-CFO: |
www.synprosis.com |
|
Clients: Pharmaceutical industry |
BusDev: Pomarède (Richard) |
|
|
Age: 17 year(s) |
Financers (Hist.): privately owned (registered capital 2007 = 0.23 M€) |
Tc Land Expression |
2002 |
Bretagne |
Design, Diagnostics |
Spin-off | |
Multiple |
Preclin |
|
Nantes |
Key words: Biomarkers, Transplantation, Auto-immune diseases |
Managing Dir.-CEO: Tchelingerian (John) [born 1965, Ph.D. neuroscience, ex-Neurotech (co-founder), Key Obs (co-founder), Diatos (CEO)] |
|
|
Mission: to develop gene expression biomarkers in transplantation and immunology through proprietary strategy of personalized medicine |
Sc.Dir.-CSO: Guillet (Marina) [born 1973, Ph.D., ex-TcLand (CEO)] |
|
|
Clients: Pharmaceutical industry, Research labs |
Clin.Dir.-CMO: Larcier (Patrick) [Pharm.D., MBA Essec, ex-Neovacs, Biogen-Idec, Quintiles, Parexel, GSK] |
www.tcland-expression.com |
|
Age: 18 year(s) |
Fin.Dir.-CFO: Jaffré (Philippe) [MBA, ex-Novartis, Chiron, Dana Capital] |
|
|
|
SalesMktg: Kazek (Elodie) [Pharm.D., ESSEC, ex-BioMerieux, Fresenius Kabi, Merck KgAa] |
|
|
|
BusDev: Payne (Peter) [Ms. pharmacology, ex-Quintiles, Wellcome, Sterling Drug, Glaxo], also Head of US-Business |
|
|
|
Financers (Hist.): Auriga Partners, Debiopharm, Genzyme Ventures, Quest For Growth, Beviguen |
|
|
|
Note: the previous URL, tcland-biotech.com, has been replaced by tcland-expression.com, late 2010 |
Theraclion |
2004 |
IDF |
Development, Devices |
Start-up | |
Multiple |
Clinical |
|
Paris |
Key words: Ultrasound, Parathyroidism, Prostate cancer, Fibroadenoma, UNIS |
Managing Dir.-CEO: Burel (Jean-Yves) [born 1951, ex-GE Healthcare] |
|
|
Mission: to develop non-invasive solutions, based on High Intensity Focussed Ultrasound (HiFu), for the non-invasive ablation of small tumors and the treatment of secondary hyperparathyroidism, thyroid nodules |
Sc.Dir.-CSO: Lacoste (François) [co-founder, born 1950, Eng. physics, ex-Technomed, Cilas-Alacatel, Perkin Elmer] |
|
|
Clients: undisclosed |
R&D Dir.-CMO: Yon (Sylvain) [born 1974, ESCPI, Ph.D. physics, ex-Echosens (co-founder)] |
www.theraclion.fr |
|
Age: 16 year(s) |
Fin.Dir.-CFO: |
|
|
|
BusDev: Del Bourgo (David) [Eng. UIT Compiègne, MBA Chicago, ex-Orbotech, Advention Business Partners, General Electric Healthcare] |
|
|
|
Financers (Hist.): Truffle Ventures |
Theradiag |
1987 |
IDF |
Discovery, Diagnostics |
Start-up | |
Allergy |
Trade |
|
Marne-la-Vallée |
(also, Design, Devices) |
Managing Dir.-CEO: Finance (Michel) [Ms. EM Lyon, ex-Neovacs, Carmat, Flamel Technologies, Aventis] |
|
(near Paris) |
Key words: Auto-immune diseases, Allergy test monitor, Caris, Fidis, Luminex |
Tech.Dir.-CTO: Parussini (Ermis), Ms.Sc. molecular biology, ex-Biomérieux |
|
|
Mission: to develop, manufacture and market quality and innovative IVD products for the diagnostic market of auto-immune diseases, allergies and infectious diseases |
Sc.Dir.-CSO: |
www.theradiag.com |
|
Clients: Pharmaceutical industry |
Sales Dir.: Sallen (Eric), Abbott, Becton Dickinson, Saint Gobain, Kottermann, Seroa] |
|
|
Age: 33 year(s) |
Admin.Dir.: François (Fabienne) [MBA, HR experience] |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): Truffle Venture (majority share), CDC Entreprise, AGF P.E., Siparex, Auriga Partners, Ventech, 123 Multinova |
|
|
|
Communication:with company name change, the URL moves and www.bmd-net.com is deleted (June 2012) |
Theralpha |
2009 |
Méditerranée |
Discovery, Drugs |
Spin-off | |
Pain |
Preclin |
|
Sophia Antipolis |
Key words: Pain, Acid-Sensing-Ion-Channel (ASIC), Sublingual |
Managing Dir.-CEO: Dellamonica (David) [ESG, MBA, ex-TxCell, Nex&Com, Polygram Universal, Ogilvy Healthcare] |
|
(near Nice) |
Mission: to develop innovative peptide-based drugs for the treatment pain |
Sc.Dir.-CSO: Lazdunski (Michel) [Ph.D., Professor, CNRS] |
|
|
Clients: Pharmaceutical industry (own development up to clinical trials) |
Fin.Dir.-CFO: |
www.theralpha.com |
|
Age: 11 year(s) |
BusDev: |
|
|
|
Financers (Hist.): privately owned (registered capital 2009 = 0.04 M€) |
TheraVectys |
2005 |
IDF |
Discovery, Immunology |
Spin-off | |
Vaccines |
Preclin |
|
Paris |
Key words: Vaccines, DNA Flap Lentivirus, Veterinary |
Managing Dir.-CEO: Gohaud (Romain) [born 1949] |
|
|
Mission: to develop new vaccines derived from the DNA Flap Lentivirus technology |
Sc.Dir.-CSO: Charneau (Pierre) [Ph.D. virology, Institut Pasteur] |
|
|
Clients: Pharmaceutical industry (own development up to clinical trials) |
Fin.Dir.-CFO: |
www.theravectys.com |
|
Age: 15 year(s) |
BusDev: |
|
|
|
Financers (Hist.): privately owned (registered capital 2006 = 0.06 M€) |
Transgene |
1979 |
Alsace |
Discovery, Immunology |
Start-up | |
Vaccines |
Clinical |
|
Strasbourg |
Key words: Therapeutic vaccines, Immuno-therapy, Cancer, Infectious diseases |
Managing Dir.-CEO: Archinard (Philippe) [born 1959, Ph.D. Biochemistry, Eng. Chemistry, ex-Innogenetics (CEO), Biomérieux] |
|
|
Mission: to discover and develop gene-based therapeutic vaccines and immunotherapy products |
Sc.Dir.-CSO: Bonnefoy (Jean-Yves) [Ph.D. immunology, ex-Pierre Fabre, Glaxo Wellcome] |
|
|
Clients: Prescribers |
Med.Dir.-CMO: Adda (Nathalie) [M.D., ex-Vertex] |
www.transgene.fr/us |
|
Age: 42 year(s) |
Fin.Dir.-CFO: Boissel (Stéphane) [MBA (Chicago), ex-PWC, Innate Pharma, Lazard] |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): Mérieux (53%), Institutional investors, AFM, Public |
Trophos |
1999 |
Méditerranée |
Discovery, Drugs |
Personal venture | |
Multiple |
Clinical |
|
Marseille |
Key words: Embryonic neurones, Parkinson’s diseases, Huntington’s diseases, Cardiac ischemia, IRIstop |
Managing Dir.-CEO: Placet (Christine) [Sup de Co (Marseille), ex-Ernst & Young] |
|
|
Mission: to develop drugs to prevent neuronal loss in patients with neurodegenerative diseases, based on proprietary screening system employing sick neurons (focused in 2009, onto neuroprotection and cardioprotection) |
Sc.Dir.-CSO: Pruss (Rebecca) [Ph.D., ex-Sanofi-Synthélabo] |
|
|
Clients: Prescribers |
Med.Dir.-CMO: Abitbol (Jean-Louis) [M.D., ex-Parke Davis, Pfizer, Pierre Fabre] |
www.trophos.com |
|
Age: 22 year(s) |
Fin.Dir.-CFO: |
|
|
|
BusDev: Harris (Stephen) [Ph.D., ex-GSK] |
|
|
|
Financers (Hist.): Société Générale Assets Management (SGAM), Turenne Capital Partners, Viveris Management, SOFIPACA, SOFIMAC OTC Asset Management, CM-CIC Asset Management, Blue Medical, AFM (French Muscular Dystrophy Association), Innoveris, business angels |
TxCell |
2001 |
Méditerranée |
Discovery, Immunology |
Spin-off | |
Inflammation |
Clinical |
|
Sophia Antipolis |
Key words: Cell Therapy, Inflammatory, Autoimmune diseases |
Managing Dir.-CEO: Meyer (François) [born 1948, Ph.D. molecular biology, ex-Ciba-Geigy, Sandoz, Rhone Poulenc Rorer, Aventis] |
|
(near Nice) |
Mission: to develop new therapies to cure inflammatory and autoimmune diseases, such as Crohn’s disease, multiple sclerosis, psoriasis or rheumatoid arthritis, by bringing regulatory T cells to the body |
Sc.Dir.-CSO: Foussat (Arnaud) [Ph.D., ex-Inserm] |
|
|
Clients: Prescribers |
Med.Dir.-CMO: Forte (Miguel) [M.D., Ph.D., ex-B.M.S., Nabi Pharmaceuticals, UCB] |
www.txcell.com |
|
Age: 19 year(s) |
Fin.Dir.-CFO: Sarlot (Christophe) |
|
|
|
BusDev: |
|
|
|
Financers (Hist.): Auriga Partners, AXA Private Equity, BioAm, CDC, SPEF Venture, Inserm-Transfert |
UROsphere |
2004 |
Midi-Pyrénées |
Contract, Research |
Spin-off | |
Multiple |
Preclin |
|
Labège |
Key words: Urinary incontinence, Benign prostatic hyperplasia (BPH), Sexual dysfunctions, Renal disorders |
Managing Dir.-CEO: Lluel (Philippe) [born 1966, Ph.D. pharmacology] |
|
(near Toulouse) |
Mission: to provide third parties with research preclinical services for urology and renal pathologies |
Sc.Dir.-CSO: Palea (Stefano) [born 1962, Ph.D. pharmaceutical chemistry, ex-Sanofi-Aventis, Glaxo-Wellcome] |
|
|
Clients: Pharmaceutical industry |
Fin.Dir.-CFO: |
www.urosphere.com |
|
Age: 16 year(s) |
BusDev: |
|
|
|
HR.Dir: Mignotte-Darmon (Brigitte) [DESS Management] |
|
|
|
Financers (Hist.): privately owned (registered capital 2006 = 0.13 M€) |
|
|
|
note (March 2010) : new website unveiled |
Vaxon Biotech |
2004 |
IDF |
Discovery, Immunology |
Personal venture | |
Vaccines |
Clinical |
|
Paris |
Key words: Therapeutic vaccines, Cryptic peptides |
Managing Dir.-CEO: Vallet (François) [born 1958, Polytechnique, Ph.D. physics, ex-Genewave (co-founder)] |
|
|
Mission: to develop innovative therapeutic vaccines for the treatment of cancer including lung, prostate, breast, renal, liver and colorectal cancer, using proprietary technology of optimized cryptic peptides |
Sc.Dir.-CSO: Kosmatopoulos (Kostas) [born 1950, M.D., Ph.D., also Chairman, ex-Inserm] |
|
|
Clients: Prescribers |
Fin.Dir.-CFO: |
www.vaxon-biotech.com |
|
Age: 17 year(s) |
BusDev: |
|
|
|
Financers (Hist.): Génopole 1er Jour (G1J), Inserm-Transfert, privately owned |
Vectalys |
2005 |
Midi-Pyrénées |
Design, Drugs |
Personal venture | |
Virus |
Preclin |
|
Labège |
(also, Contract, Resarch) |
Managing Dir.-CEO: Bouillé (Pascale) [born 1967, founder, Ph.D. molecular biology, secretary JEInnov] |
|
(near Toulouse) |
Key words: Gene sequences, Gene transfer, Viral vector, Retrovirus, Lentivirus |
Sc.Dir.-CSO: |
|
|
Mission: to provide third parties with a platform of retroviral (RV), lentiviral (LV) and adeno-associated virus (AAV) based vectors that efficiently introduce human gene sequences into a wide variety of human cells to knock-in or knock-down specific proteins |
Fin.Dir.-CFO: |
www.vectalys.com |
|
Clients: Pharmaceutical industry |
BusDev: |
|
|
Age: 15 year(s) |
Financers (Hist.): pricately owned (registered capital 2006 = 0.05 M€) |
Vivalis |
1999 |
Bretagne |
Design, Manufacture |
Start-up | |
Multiple |
Preclin |
|
Nantes |
(also, Discovery, Immunology) |
Managing Dir.-CEO: Grimaud (Franck) [co-founder, born 1966, MBA] |
|
|
Key words: Vaccines, Flu, Viral diseases, EBx Cell line, Therapeutic protein, Cell Culture, EB66 |
Sc.Dir.-CSO: Mehtali (Majid) [Ph.D., ex-Deltagen, Transgene, Rhône Mérieux] |
|
|
Mission: to provide innovative cell-based solutions for the industrial manufacture of viral vaccines and therapeutic proteins, and to develop own vaccines and drugs in order to prevent and treat viral diseases (also deeply involved in veterinarian vaccines) |
Fin.Dir.-CFO: Rousseau (Philippe) [HEC, ex-Exonhit, Valigen, Genset, Mars, Paribas] |
www.vivalis.com |
|
Clients: Pharmaceutical industry (own development up to clinical trials) |
BusDev: Miniou (Pierre) [Ph.D., ex-Pierre Fabre, Transgene] |
|
|
Age: 21 year(s) |
Financers (Hist.): Grimaud-La Corbière Group, Public |
|
|
|
Note : company legal domiciliation : Roussay (49) |
XenTech |
2006 |
IDF |
Contract, Research |
Spin-off | |
Cancers |
Preclin |
|
Évry |
(also, Discovery, Diagnostics) |
Managing Dir.-CEO: Coulomb (Bertrand) [born 1955, Pharm.D., ex-Nycomed, Altana Pharma, Pasteur-Sanofi Diagnostics, UPSA (BMS), Servier] |
|
(near Paris) |
Key words: Theranostics, Preclinical oncology, Tumor models |
Sc.Dir.-CSO: Judde (Jean-Gabriel) [co-founder, born 1954, Ph.D., ex-MD Anderson Cancer Center, NCI, Institut Curie, also board chairman] |
|
|
Mission: to provide specialized services in predictive preclinical oncology, to develop own treatment diagnostics derived from patient-derived tumor xenografts |
Oper.Dir.-COO: Leuraud (Pascal) [co-founder, Ph.D.] |
www.xentech.eu |
|
Clients: Pharmaceutical industry, Biotechs, Research labs |
Fin.Dir.-CFO: |
|
|
Age: 14 year(s) |
BusDev: Bazzacco (Paola) |
|
|
|
Financers (Hist.): privately owned (registered capital 2007 = 0.05 M€), Aurinvest Capital 2 |